The post Physalis Alkekengi appeared first on The Robert Scott Bell Show.

Friday on The Robert Scott Bell Show:

Hour 1

Why Government Schools Don’t Want You to Understand Economics In a November 1, 2026, article published by the Mises Institute in The Misesian, the organization examines the relationship between government-controlled education and economic literacy, arguing that public schools have institutional incentives to avoid teaching economic principles that might encourage students to question government intervention. The article summarizes a September 12 conference held at the Westin Poinsett in Greenville, South Carolina, where five Mises Institute scholars discussed public education, economic theory, homeschooling and the future of higher education. Tate Fegley opened the conference with a presentation examining why publicly funded schools may be reluctant to teach economic concepts that challenge the institutions financing and administering them. His argument focused on the incentives facing government educational bureaucracies and the possibility that those incentives influence curriculum decisions. Economist Paul Cwik followed with a presentation addressing what he considers deficiencies in public education and advocating homeschooling, educational cooperatives and greater parental involvement as alternatives. Mark Thornton discussed the ideological assumptions students encounter throughout their education, arguing that schools and universities frequently present economic and political ideas from perspectives that favor government intervention. Jonathan Newman examined economic concepts he believes are inadequately addressed in conventional curricula, including arguments associated with the Austrian school of economics. He also highlighted educational resources available through the Mises Institute and Mises Academy. Peter Klein concluded the individual presentations by examining how artificial intelligence could change universities, educational delivery and the traditional structure of higher education. During a subsequent panel discussion, participants considered ways to challenge Keynesian economic arguments, possible state-level education reforms and how a more competitive educational marketplace might operate. A recurring theme was that economic understanding provides individuals with tools to evaluate government policies independently, including taxation, regulation, public spending and market intervention. The speakers argued that a population familiar with economic incentives and unintended consequences may be better equipped to question government programs and recognize the limitations of centralized planning. However, the article primarily summarizes the conference speakers’ viewpoints rather than presenting independent research demonstrating that public school administrators deliberately suppress economic education. Public schools vary substantially in curriculum, educational quality and the economic perspectives presented to students. Supporters of public education also argue that publicly funded schools can expand educational access and provide opportunities for civic and economic literacy. The Mises Institute approaches these questions from its established Austrian-school and free-market perspective, emphasizing individual liberty, private property and skepticism toward centralized authority. The broader significance of the article is its argument that education influences how future generations understand the relationship between government and the economy, and that greater educational choice and exposure to competing economic theories could encourage more independent evaluation of public policy.

Why a US-funded vaccine trial on babies was cancelled in Guinea-Bissau A BBC report examines the cancellation of a controversial United States-funded clinical trial involving newborn babies in Guinea-Bissau, where researchers proposed studying whether the timing of hepatitis B vaccination influenced overall infant health outcomes. The planned study, developed by researchers associated with the Bandim Health Project and the University of Southern Denmark, would have enrolled approximately 14,000 newborns and randomly assigned them to receive hepatitis B vaccination either immediately after birth or at six weeks of age. Researchers sought to investigate whether the vaccine produced effects beyond protection against hepatitis B infection, including possible differences in overall illness and mortality. The project was expected to receive approximately $1.6 million from the U.S. Centers for Disease Control and Prevention, with additional support from private funding sources. Supporters argued that the study could provide useful evidence about the broader biological effects of childhood vaccination and help inform immunization policies in countries with limited healthcare resources. However, the proposal generated substantial ethical concerns because the World Health Organization recommends administering the first hepatitis B vaccine dose within 24 hours of birth to reduce the risk of infection transmitted from mother to child. Hepatitis B can establish chronic infection during infancy and increase the risk of serious liver disease, cirrhosis and liver cancer later in life. Critics questioned whether delaying vaccination for research purposes could expose participating infants to avoidable risks, particularly when the intervention under investigation already has established preventive benefits. The controversy also involved informed consent, the responsibilities of foreign-funded researchers and whether the trial had received appropriate authorization from Guinea-Bissau’s government. Although researchers maintained that the delayed-vaccination group would follow the country’s existing immunization schedule, international health authorities argued that the study should not postpone access to a recommended preventive measure. Guinea-Bissau’s health officials ultimately refused to authorize the project, and the country’s Council of Ministers reaffirmed that decision in October 2026. Authorities subsequently intervened in preparations for the study, and researchers confirmed that enrollment had not begun and that no infants had received study vaccines. The cancellation therefore occurred before the proposed intervention was implemented. The dispute illustrates the difference between scientific questions that researchers consider worth investigating and the ethical requirements governing studies involving vulnerable populations. It also raises questions about the role of American public health funding in international medical research and the authority of host countries to determine whether proposed experiments meet their standards. The broader significance concerns the balance between scientific investigation, established preventive care, parental consent and the protection of infants participating in clinical research.

Congress Will Have At Least 18 Physicians—Here’s What It Could Mean For Public Health In a November 5, 2026, Forbes article, physician and public health commentator Dr. Omer Awan examines the potential influence of an unusually large number of medical professionals entering Congress following the midterm elections. At least 18 physicians are expected to serve in the 120th Congress beginning in January 2027, with the total potentially reaching 21 depending on the results of outstanding races. This would establish a record for physician representation in Congress. The incoming group currently includes 10 Democrats and eight Republicans, representing specialties such as pediatrics, emergency medicine, surgery and epidemiology. Among the newly elected members are South Carolina pediatrician Dr. Annie Andrews and Michigan physician and epidemiologist Dr. Abdul El-Sayed. Awan argues that lawmakers with direct clinical experience may bring valuable perspectives to debates about healthcare financing, insurance coverage, medical affordability, disease prevention and federal public health policy. Physicians regularly encounter patients whose medical conditions are complicated by inadequate insurance, delayed diagnoses, expensive prescriptions and limited access to routine care. According to Awan, these experiences may help legislators better understand how federal policies affect individual patients and healthcare institutions. He identifies healthcare affordability as a particularly important issue, noting that nearly half of American adults have inadequate health insurance coverage according to surveys cited in the article. Rising premiums, hospital expenses and prescription drug costs could therefore become major areas of legislative attention. Democratic lawmakers have emphasized restoring enhanced Affordable Care Act premium subsidies and addressing reductions in Medicaid funding, while El-Sayed campaigned on expanding healthcare access through Medicare for All. The article also examines how physician lawmakers might influence vaccine policy and infectious disease preparedness. Awan points to measles outbreaks, declining vaccine confidence and changes affecting federal health agencies as issues requiring congressional attention. He argues that clinicians may contribute practical knowledge when lawmakers evaluate recommendations from the Centers for Disease Control and Prevention, the Food and Drug Administration and other public health institutions. However, physicians do not necessarily share identical views on vaccination, federal regulation, insurance systems or the appropriate role of government in medicine. Their professional training may inform their positions without eliminating ideological differences. Awan identifies prescription drug affordability, physician shortages and support for rural hospitals as subjects where bipartisan cooperation may be possible. He also acknowledges that medical qualifications alone do not guarantee effective legislation or improved health outcomes. Congressional decisions involve competing financial priorities, constitutional responsibilities, political negotiations and considerations extending beyond clinical medicine. The article’s broader significance is the potential for greater medical expertise within federal policymaking, while recognizing that the practical impact of physician representation will depend on whether lawmakers can translate professional experience into legislation that addresses healthcare costs, access and public health needs.

LGBT Caucus Celebrates “Gayest Congress In American History” In a November 5, 2026, article published by Not the Bee, writer Cardinal Pritchard reacts to a social media announcement from the Congressional Equality Caucus celebrating what it describes as the largest representation of openly LGBTQ members in American congressional history. Following the November 3 midterm elections, the caucus posted a message on X declaring that the incoming 120th Congress would have a record number of openly LGBTQ lawmakers. The announcement included a rainbow-themed graphic and American, rainbow pride and transgender pride flag symbols, presenting the election results as a milestone for political representation. The Not the Bee article approaches the announcement through sarcasm and political humor rather than conventional news analysis. Pritchard expresses disbelief at the caucus’s celebratory language, references Senator Lindsey Graham in a joke and highlights critical social media reactions to the announcement. The commentary reflects frustration among some conservative observers who believe congressional leaders should emphasize economic affordability, government accountability and other policy priorities rather than celebrating the personal identities of elected officials. The underlying electoral development is nevertheless significant. Reports following the election indicate that 16 openly LGBTQ candidates won congressional races, with the incoming Congress expected to include two openly LGBTQ senators and 15 voting representatives. New Hampshire Democrat Chris Pappas, previously a member of the House of Representatives, was elected to the Senate and is expected to join Wisconsin Senator Tammy Baldwin, becoming the first openly gay man to serve in that chamber. Newly elected LGBTQ House members include candidates from New York, Indiana, Arizona, Michigan and California. The Congressional Equality Caucus was established in 2008 by lawmakers including Tammy Baldwin and Barney Frank to advocate for legislation addressing discrimination, equal rights and the treatment of LGBTQ Americans. Its policy priorities have included the Equality Act, legislation intended to expand federal civil rights protections involving sexual orientation and gender identity. Supporters argue that increased representation can provide perspectives from communities historically underrepresented in federal government and can influence legislative discussions involving employment, housing, healthcare and civil rights. Critics raise questions about the implications of some proposed policies for religious liberty, sex-based legal distinctions and the proper scope of federal civil rights regulation. The Not the Bee article does not offer a detailed examination of these legislative questions, focusing instead on the announcement’s wording and the public reaction it generated. The number of openly LGBTQ lawmakers is a descriptive measure of representation, not evidence by itself that Congress will adopt particular policies or improve legislative performance. The broader significance is the growing visibility of LGBTQ elected officials and the continuing political disagreement over how identity, representation and policy priorities should be discussed in American government.

Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!

Today’s Homeopathic Hit is Physalis alkekengi, or Winter Cherry.

Boericke emphasizes urinary gravel, lithiasis, altered urine output, and incontinence, alongside weakness, head symptoms, and respiratory irritation.

Download the  Information Sheet

Hour 2

Pesticide Lobby Celebrates Influence Over MAHA Strategy as ‘Most Significant Accomplishment’ of 2025 In a November 4, 2026, investigation by Stacy Malkan of U.S. Right to Know, republished by Children’s Health Defense, documents how pesticide industry lobbying influenced the Trump administration’s Make America Healthy Again Commission and contributed to the removal of proposed pesticide restrictions from its final strategy. The central evidence comes from CropLife America’s 2025 Impact Report, in which former board chairman Paul Rea, a longtime BASF executive, identified the organization’s campaign to influence MAHA policy as its most significant accomplishment of the year. CropLife represents major pesticide manufacturers, including Bayer, BASF, Corteva, FMC and Syngenta. When President Trump established the MAHA Commission in February 2025 under Health Secretary Robert F. Kennedy Jr., the initiative promised to investigate chronic disease, particularly among children, and address potentially harmful environmental exposures. Its initial May 2025 report raised concerns about glyphosate and atrazine, two widely used herbicides, along with corporate influence over scientific research and regulatory decisions. Pesticide manufacturers responded with an extensive lobbying campaign, arguing that additional restrictions could threaten agricultural production, increase food costs and undermine farmers’ access to important crop protection products. According to CropLife’s own report, the effort included approximately 5,200 letters from farmers, meetings with administration officials, congressional coordination, paid advertising and a messaging campaign called Farmers Voices Matter. CropLife President Alexandra Dunn, who previously led the Environmental Protection Agency’s chemical safety division, described the White House as receptive to the industry’s concerns. The September 2025 MAHA strategy ultimately omitted proposed restrictions on specific pesticides and instead emphasized public confidence in the EPA’s existing pesticide evaluation system. CropLife celebrated that outcome as a victory for agriculture and pesticide manufacturers. MAHA advocates interviewed by Malkan, including Kelly Ryerson, Vani Hari and Farm Action President Angela Huffman, criticized the changes, arguing that the administration had placed industry interests ahead of its commitments to investigate environmental contributors to chronic disease. Former Kennedy adviser Calley Means also expressed frustration with corporate influence over agricultural and health policy. The investigation examines relationships between pesticide companies and administration officials, reporting that CropLife spent more than $84 million advancing industry interests since 2020 and that numerous officials had previously worked within Bayer’s lobbying or legal network. It also describes communications involving former Corteva lobbyist Turner Bridgeforth, who subsequently served as a senior EPA adviser, and Bayer’s efforts to influence federal litigation involving Roundup. CropLife responded that it shares the MAHA Commission’s goal of improving children’s access to nutritious food and supports policies based on scientific evidence. The documented lobbying campaign and changes between the commission’s initial and final reports support scrutiny of industry influence, although they do not independently establish that every policy decision resulted from improper conduct. The broader significance is the tension between MAHA’s commitment to reducing potentially harmful environmental exposures and the political influence of industries whose products could face additional regulation. The investigation raises questions about transparency, conflicts of interest and whether federal health policy can remain independent when powerful commercial stakeholders participate extensively in its development.

Omega-3 DHA Eases Autism Behaviors by Calming Inflammation In a November 3, 2026, article published by Neuroscience News, researchers describe a preclinical study suggesting that docosahexaenoic acid, or DHA, an omega-3 fatty acid important for brain development, may reduce certain autism-like behaviors in laboratory rats by suppressing inflammation and strengthening antioxidant defenses in the brain. The research, published in the journal Pediatric Discovery, was conducted by scientists associated with Chongqing Medical University and Guangzhou Women and Children’s Medical Center in China. Investigators used a neonatal maternal separation model, in which young rats were separated from their mothers for three hours daily during their first 21 days of life and subsequently housed individually until day 56. This experimental procedure produces behavioral changes involving social interaction, repetitive activity and anxiety that researchers use to investigate selected features associated with neurodevelopmental conditions. The animals received DHA at a dose of 80 milligrams per kilogram of body weight daily through intraperitoneal injection, rather than through ordinary dietary supplementation. Researchers observed that treated rats spent more time interacting with unfamiliar animals, demonstrated less repetitive self-grooming and displayed reduced anxiety-like behavior during standardized laboratory assessments. The investigation also examined biochemical changes in the prefrontal cortex, a brain region involved in executive function, behavioral regulation and social cognition. DHA treatment reduced activation of the c-Jun N-terminal kinase, or JNK, signaling pathway, which participates in cellular stress and inflammatory responses. Researchers observed lower concentrations of inflammatory signaling molecules, including tumor necrosis factor alpha, interleukin-6 and interleukin-1 beta. At the same time, DHA increased activity associated with NRF2, a regulatory pathway that helps cells respond to oxidative stress, along with antioxidant proteins and enzymes including HO-1, superoxide dismutase 1 and catalase. Computational molecular modeling and laboratory measurements were used to investigate how DHA might influence these processes. The authors propose that reducing neuroinflammation and oxidative stress may help explain the behavioral improvements observed in their experimental animals. However, the study does not establish that DHA treats autism in humans. The maternal separation model reproduces selected behaviors associated with autism but does not represent the full biological and developmental complexity of autism spectrum disorder. The administered dose, injection method and experimental conditions also differ substantially from normal human consumption of omega-3-rich foods or supplements. Previous clinical investigations of omega-3 supplementation in autistic individuals have produced mixed findings, and the new animal results cannot determine whether comparable benefits would occur in children or adults. Researchers recommend further studies examining appropriate doses, treatment timing, safety and whether specific populations with elevated inflammatory or oxidative stress markers might benefit. The broader significance is the identification of potentially relevant biological pathways connecting fatty acid metabolism, inflammation and neurodevelopment, providing a basis for future research without establishing DHA as a proven autism treatment.

GLP-1 Drugs Beat Standard Prediabetes Treatment A November 4, 2026, Newsmax health report addresses preliminary research suggesting that GLP-1-based medications may offer greater protection against the progression of prediabetes to type 2 diabetes than metformin, a widely prescribed and comparatively inexpensive treatment. The findings, released ahead of the American Heart Association’s Scientific Sessions 2026 in Chicago, come from an observational analysis of electronic health records involving 256,492 adults diagnosed with both prediabetes and obesity. Researchers examined records from 104 healthcare institutions covering 2010 through 2023, with participants followed for approximately three years on average. The patients had an average age of 52, and approximately 76% were women. Investigators compared people prescribed metformin with those receiving GLP-1-based medications, including semaglutide, tirzepatide, liraglutide and dulaglutide. To improve comparability, researchers matched patients according to age, existing health conditions and other medication use. The results indicated that people receiving GLP-1 medications were approximately 1.5 times as likely to return to normal blood sugar levels as those taking metformin. They also experienced a 31% lower relative risk of developing type 2 diabetes and a 41% lower relative risk of death from any cause. Cardiovascular outcomes showed additional associations, including 15% fewer heart attacks, 20% fewer strokes, 25% fewer heart failure events and 8% fewer cases of atrial fibrillation. Lead researcher Dr. Vinicius de Sousa Barzon Serra, a cardiovascular medicine research fellow at the Mayo Clinic in Scottsdale, Arizona, suggested that the results could support considering GLP-1 medications earlier for selected patients rather than waiting until type 2 diabetes develops. However, he emphasized that metformin remains an important first-line treatment because of its established safety record, affordability and extensive clinical experience. Former American Heart Association president Dr. Robert Eckel suggested that the observed benefits may be related substantially to weight loss, which can improve insulin sensitivity and reduce cardiovascular risk. The study’s observational design is an important limitation because it cannot demonstrate that GLP-1 treatment directly caused the better outcomes. Researchers also relied on prescription records rather than verified medication use and analyzed several different GLP-1 drugs as one group, limiting conclusions about individual medications. The findings were presented as a conference abstract and had not yet been published as a complete peer-reviewed study. The researchers emphasized that dietary changes, exercise and weight management remain essential components of prediabetes care. The broader significance is that GLP-1 medications may eventually have an expanded role in diabetes prevention, although cost, accessibility, side effects and stronger clinical evidence will influence how widely they are prescribed.

Obesity drugs could lead to new ways to protect the brain In a November 6, 2026, article published by Medical Xpress, researchers from the University of Gothenburg and the University of Copenhagen examine whether medications currently used to treat obesity and type 2 diabetes could eventually provide new approaches to protecting cognitive function. The report describes a scientific review published in the journal Science by Stina Börchers and colleagues, titled Obesity Pharmacotherapies and Cognition. The researchers evaluated existing evidence concerning drugs such as semaglutide and tirzepatide, which influence appetite, blood glucose regulation and metabolic processes through hormone-related signaling pathways. Although these medications are primarily prescribed for weight management and diabetes, their biological effects may extend to systems involved in memory, learning and other aspects of brain function. Animal experiments have suggested that GLP-1-related treatments can influence learning and memory, while observational studies involving people with type 2 diabetes have associated treatment with lower rates of dementia. However, the researchers emphasize that such associations do not establish whether the medications themselves provide direct neurological protection. People receiving these drugs may experience improvements in blood glucose regulation, body weight, cardiovascular health and other metabolic factors that independently influence cognitive outcomes. The review also addresses important clinical evidence that has challenged earlier expectations. Novo Nordisk’s EVOKE and EVOKE+ clinical trials investigated semaglutide in people with early Alzheimer’s disease but did not demonstrate that the medication slowed disease progression, despite changes in certain biological markers. Those findings limit claims that semaglutide is an effective treatment for established Alzheimer’s disease, but they do not rule out possible benefits in other patient populations or at earlier stages of cognitive decline. Börchers explains that people with obesity and type 2 diabetes may experience difficulties involving attention, planning and information-processing speed, partly because of metabolic and vascular disturbances. Researchers therefore want to determine whether improving those underlying conditions can help preserve cognitive abilities before significant impairment develops. Senior author Christoffer Clemmensen emphasizes the need to distinguish between direct effects of these medications on the brain and indirect benefits resulting from improved metabolic health. That distinction could eventually help scientists develop more targeted treatments intended specifically to preserve cognition. The researchers recommend future clinical trials that measure memory and other cognitive abilities from the beginning of treatment rather than relying exclusively on medical records or indirect disease markers. They also caution that rapid weight loss can reduce muscle mass, particularly in older or physically frail patients, potentially undermining functional health despite improvements in metabolic measurements. The review does not establish that obesity medications prevent dementia or reverse neurological disease. Instead, it identifies promising biological questions and emphasizes the need for carefully designed human studies. The broader significance is the growing recognition that metabolic health and brain function are closely connected, potentially opening new directions for research into cognitive decline, obesity and diabetes.

Tony Lyons: The Reports of MAHA’s Death Are Greatly Exaggerated In a November 5, 2026, statement published by The MAHA Report, Tony Lyons responds to disappointing midterm election results for candidates associated with the Make America Healthy Again movement and argues that the political setbacks do not represent the end of MAHA’s influence. Introducing the MAHA Weekly Media Hub, Lyons acknowledges that several candidates supported by the movement lost their races, including Zach Lahn in Iowa, whose campaign he praises for its organization, message and determination despite facing well-funded opposition. Lyons argues that MAHA candidates encountered substantial resistance from powerful political, corporate and media interests, including organizations associated with the pharmaceutical, agricultural and processed-food industries. He suggests that negative coverage before the election contributed to a broader narrative portraying the Democratic victories as a rejection of MAHA’s health policy priorities. However, he maintains that election results should not be confused with public attitudes toward individual health issues. Lyons identifies vaccine safety, possible adverse reactions to medical products, ultra-processed foods, pesticide exposure, chronic disease and government accountability as subjects that have become increasingly prominent in public discussion. He argues that these concerns will remain politically relevant regardless of which party controls Congress. As evidence of the movement’s continuing support, he cites an Iowa NBC poll in which approximately one-third of respondents reportedly identified as MAHA supporters. He also claims that roughly half of candidates supported or endorsed by MAHA-affiliated political organizations won their races despite broader Democratic gains. Among the candidates he highlights are Julia Letlow in Louisiana, Anna Paulina Luna in Florida, Jace Yarbrough in Texas, Michael Alfonso in Wisconsin and Austin Rogers in Florida. These electoral examples are presented as evidence of continued political organization, although the article does not provide a comprehensive independent analysis of the movement’s national electoral performance. Lyons emphasizes that MAHA’s original objective was not simply to win a particular election but to reduce chronic disease and change the country’s approach to public health. He calls for a broader coalition involving Republicans, Democrats, independent voters, activists, nonprofit organizations, healthcare professionals and businesses willing to address shared health concerns. His proposed strategy emphasizes expanding partnerships across ideological divisions rather than treating the movement as permanently attached to one political party. Lyons also introduces a discussion featuring Florida Surgeon General Dr. Joseph Ladapo, Children’s Health Defense CEO Mary Holland and Moms Across America founder Zen Honeycutt, presenting them as examples of individuals working on health-related issues before MAHA became a prominent political movement. Throughout the statement, Lyons attributes substantial political influence to large commercial interests, although his suggestions of coordinated opposition are presented as his interpretation rather than independently established findings. The article’s broader significance is the movement’s attempt to adapt to a changed political environment by separating its long-term public health agenda from immediate electoral outcomes. Lyons argues that MAHA’s future depends on continued public engagement, organizational development and cooperation across political boundaries rather than relying exclusively on federal officeholders.

Remember Friends, The Power to Heal is Yours!

The post School Economics Blindspot, Guinea-Bissau Vaccine Trial, Congress Gains More MDs, LGBT Celebrates “Gayest Congress”, Physalis Alkekengi, Pesticide Lobby Influence, Omega-3 Autism Breakthrough, GLP-1 Prediabetes, Obesity Drugs Brain Protection, MAHA Alive and Well and MORE! appeared first on The Robert Scott Bell Show.

The post Cadmium Sulphuratum appeared first on The Robert Scott Bell Show.

Thursday on The Robert Scott Bell Show:

Hour 1

Special Guest: Jonathan Emord

For the past 37 years, Jonathan W. Emord has litigated against the federal bureaucracy, winning over and over again. Ron Paul calls Jonathan “an expert in constitutional theory and history” and “an expert litigator with a long string of legal victories over the federal bureaucracy.” George Noory calls him “a Knight in Shining Armor” and “a warrior out to save our rights.” Congressmen Dan Burton and John Doolittle describe him as “an intellectual warrior for the rights and freedoms of people in America.” Jonathan has a unique, detailed knowledge of the federal bureaucracy, the deep state. He knows how to defeat it. Jonathan graduated from the University of Illinois (BA, political science and history, 1982) and DePaul University College of Law (JD, 1985). He served as an attorney in the Federal Communications Commission during the Reagan administration. A leading constitutional law and litigation expert, he is the author of five critically acclaimed books. He has won more cases against the Food and Drug Administration in federal court than any other attorney in American history, earning him the nickname “FDA Dragon Slayer.” He is a columnist for Townhall.com, PJ Media.com, Americangreatness.com, and the U.S.A. Today Magazine. He frequently appears on national radio and television programs. He is married to Sheryl Emord, and they have two children, twins Justice and Angelica. They reside in Clifton

Trump Congratulates Democrats, Notes Iran War Played a Role In a November 4, 2026, Breitbart News article, reporter Simon Kent examines President Donald Trump’s reaction to the Democratic Party’s sweeping victories in the November 3 midterm elections, which gave Democrats control of both chambers of Congress and ended unified Republican control of the federal government. During a telephone interview with Fox News, Trump congratulated Democrats on their electoral performance while rejecting the suggestion that the results represented a personal repudiation of his presidency. He acknowledged that Democrats had achieved a political objective they had pursued for years and said he was prepared to work with the incoming congressional majority on legislation where common ground could be found. At the same time, Trump emphasized that he would retain presidential veto authority and could reject legislation advanced by Democratic lawmakers. A central focus of the article is Trump’s acknowledgment that the ongoing U.S.-Israel war against Iran contributed to Republican losses. The conflict has affected energy markets and increased costs for American consumers, creating additional economic pressures during an election in which affordability was a major concern. Trump described the Iran conflict as one factor in the outcome but defended his administration’s military actions, arguing that voters also recognized their importance. The president additionally suggested that Republican candidates suffered because he was not personally on the ballot, asserting on Truth Social that his presence would have produced a substantially different result. That statement represents Trump’s political assessment rather than a conclusion established by election data. Breitbart also reports that a White House official described the administration’s immediate reaction as defiant rather than discouraged. The official attributed part of the outcome to candidate quality and differences in voter turnout between presidential and midterm elections, while emphasizing that Trump intended to continue opposing Democratic policies. The article recalls Trump’s earlier statements that he would make extensive use of the veto if Democrats gained congressional control. The incoming 120th Congress is scheduled to take office in January 2027, leaving Trump to serve the final two years of his presidential term with an opposition-party legislature. This arrangement will substantially alter the administration’s ability to advance legislation, approve spending priorities and manage congressional oversight. Democrats will gain opportunities to initiate investigations, control committee agendas and advance their own legislative proposals, although measures requiring presidential approval will remain subject to negotiation or veto. The article’s broader significance is the transition from unified Republican government to divided government, with the Iran conflict, inflation and voter dissatisfaction contributing to a changed political environment. Trump’s response indicates a willingness to negotiate selectively while preserving executive authority to resist legislation that conflicts with his administration’s priorities.

Progressives fume at Hakeem Jeffries for saying Democrats won’t ‘get even’ with Trump In a November 4, 2026, Fox News article, reporter CJ Womack examines disagreements among Democrats over how the party should use its newly acquired congressional majorities following the midterm elections. House Democratic Leader Hakeem Jeffries, who is positioned to become speaker when the new Congress convenes, told MS NOW’s Morning Joe that Democrats should concentrate on reducing living costs and delivering practical results rather than pursuing political retaliation against President Donald Trump and his administration. Jeffries argued that voters had supported Democrats because of economic concerns, particularly the affordability of everyday necessities, and that the party should prioritize those issues when exercising its new legislative authority. His remarks prompted criticism from progressive commentators and academics who believe the incoming majority has an obligation to investigate alleged misconduct by administration officials and pursue accountability where warranted. Princeton University historian Kevin Kruse criticized Jeffries’ framing and highlighted statements from House Oversight Democrats indicating that they intended to use their investigative authority. University of Michigan professor Ebony Elizabeth Thomas argued that accountability should be understood as a matter of justice rather than personal revenge. Progressive commentator Brian Tyler Cohen offered a related perspective, maintaining that pursuing investigations and delivering economic improvements are compatible objectives rather than competing priorities. He argued that voters expect both responsive government and consequences when public officials abuse their authority. The article notes that Representative Robert Garcia of California is expected to lead the House Oversight Committee, placing him in a position to direct investigations and potentially issue subpoenas concerning administration activities. Jeffries subsequently clarified that his opposition to retaliation did not mean Democrats would abandon oversight or accountability. He emphasized that investigations should follow available evidence, comply with applicable law and remain consistent with constitutional requirements. Fox News also references an earlier interview in which Jeffries identified the Judiciary and Oversight committees as central to potential investigations while declining to categorically endorse or reject impeachment proceedings. The White House responded by stating that Trump remained willing to cooperate with Democrats on legislation benefiting Americans but would oppose investigations it regarded as politically motivated. The disagreement illustrates a broader strategic question confronting Democrats after their electoral victories: whether to devote their initial attention primarily to economic legislation, congressional investigations or a combination of both. Although Democrats will control congressional committees and can pursue oversight without presidential approval, enacting major policy changes will still require navigating Senate procedures and the possibility of a presidential veto. The distinction between legitimate oversight and partisan retaliation will likely remain politically contested, particularly when investigations concern individuals associated with the opposing party. The article’s central significance is the tension between the Democratic leadership’s emphasis on governing and the expectations of progressive activists who view accountability as an essential component of the party’s electoral mandate.

Jefferson, Secession, and “All Men Are Created Equal” In a November 3, 2026, essay published by the Mises Institute, political commentator Ryan McMaken examines the historical meaning of Thomas Jefferson’s declaration that all men are created equal and argues that the phrase was originally intended to establish universal natural rights rather than justify government-enforced equality of income, social status or individual abilities. McMaken contends that modern political movements frequently invoke Jefferson’s language to support federal intervention in state and local affairs, economic redistribution and other policies intended to reduce disparities. He argues that such interpretations differ from the classical liberal philosophy associated with the American founding. Drawing on the writings of economist Murray Rothbard, McMaken explains that equality in the eighteenth-century liberal tradition referred primarily to equal liberty and opposition to legally established privileges. Under European mercantilist systems, governments frequently granted monopolies, commercial advantages and special legal protections to favored individuals and businesses. Classical liberals challenged these arrangements because they restricted economic opportunity and gave politically connected groups advantages unavailable to others. McMaken connects Jefferson’s language to the Virginia Declaration of Rights, which described human beings as naturally free and independent, and argues that the Declaration of Independence applied this principle to the American colonies’ right to separate from British authority. In this interpretation, political legitimacy derives from natural rights possessed by individuals rather than privileges granted by a government. The article also examines nineteenth-century disputes over the Declaration’s meaning, particularly the arguments of South Carolina political leader John C. Calhoun. McMaken describes Calhoun’s opposition to Jefferson’s equality principle as closely connected to his defense of slavery and the political interests of the Southern planter class. Calhoun rejected the idea that human beings were naturally equal and argued that the Declaration’s equality language was unnecessary to justify American independence. Abolitionists, by contrast, used the principle of universal equality to challenge slavery and argue that natural rights could not legitimately be restricted according to race. McMaken emphasizes that Calhoun’s conception of secession differed from Jefferson’s. According to the essay, Calhoun viewed secession primarily as a constitutional or contractual right belonging to states, while Jefferson’s natural-rights framework supported a broader principle under which people could withdraw their political allegiance from an oppressive government. McMaken therefore argues that Jefferson’s equality language was essential to the philosophical justification for American independence rather than an unnecessary rhetorical addition. His analysis is grounded in a libertarian interpretation of founding-era political thought, and historians continue to debate how Jefferson’s universal language should be understood alongside his ownership of enslaved people and the exclusions embedded in early American political institutions. The essay does not establish that every modern policy promoting equal opportunity or civil rights contradicts Jefferson’s principles. Rather, it presents a particular distinction between equality before the law and government efforts to produce equal social or economic outcomes. The broader significance is the continuing influence of the Declaration of Independence on debates over individual rights, federal authority, political equality and the philosophical foundations of American self-government.

Republicans Deserve to Lose, but Democrats Do Not Deserve to Win. In a November 3, 2026, commentary published by the Mises Institute, former Congressman Ron Paul criticizes both major American political parties, arguing that Republican economic and foreign policies have contributed to public dissatisfaction while Democratic proposals offer an alternative he considers equally inconsistent with limited government and individual liberty. Writing as voters prepared for the midterm elections, Paul identifies rising living costs as a central reason Republicans faced significant electoral losses. He cites a 3.7% annual increase in the Consumer Price Index and a reported 0.6% decline in inflation-adjusted private-sector wages and salaries, arguing that Americans continued to experience financial pressure despite campaign promises to improve affordability. Paul notes that Trump returned to the presidency in 2025 after emphasizing lower costs and economic improvement, yet gasoline and food prices subsequently increased. He attributes part of that inflation to the U.S.-Israel war against Iran, particularly the disruption of oil supplies following Iran’s closure of the Strait of Hormuz. Higher energy prices, he argues, increased transportation and production costs throughout the economy. Paul also criticizes the financial burden of the conflict, contrasting a Pentagon estimate of approximately $47 billion with a broader estimate of $103 billion for the first four months of fighting from Stephen Semler of the Security Policy Reform Institute. These estimates use different accounting assumptions and should not be treated as directly interchangeable measures of identical expenditures. Paul places the war costs within the context of a federal debt that he reports had already reached approximately $38.5 trillion before the conflict. He argues that Republicans have failed to honor promises to restrain spending, avoid foreign military interventions and protect the purchasing power of American households. However, Paul rejects the idea that Democratic electoral success necessarily offers a satisfactory policy alternative. He criticizes Democratic support for expanded welfare programs, single-payer healthcare, higher taxes and economic policies associated with modern monetary theory. In his view, these approaches risk increasing government spending, distorting economic incentives and reducing the purchasing power of the dollar. Paul also expresses concern that some Democrats who oppose the Iran war nevertheless support continued American military assistance to Israel or Ukraine. He suggests that libertarians and antiwar members of both parties could cooperate on reducing foreign military involvement despite disagreements on domestic economic policy. The essay additionally criticizes Trump’s preference for lower interest rates, arguing that monetary expansion and artificially suppressed borrowing costs can contribute to currency depreciation and future economic instability. These economic conclusions reflect Paul’s Austrian-school and libertarian perspective; economists disagree about the effects of fiscal spending, monetary policy, taxation and public healthcare programs. His central argument is that the country’s problems cannot be resolved merely by replacing one political party with another when both support policies that expand federal authority. The broader significance is his criticism of the two-party political system and his contention that a more consistent commitment to limited government, sound money, noninterventionist foreign policy and individual liberty is necessary to address the economic and political challenges facing the United States.

Medicare For All And Public Option Are Back After Big Wins For Democrats In a November 4, 2026, Forbes article, healthcare journalist Bruce Japsen examines the renewed momentum behind Medicare for All and a government-sponsored public health insurance option following Democratic victories in the midterm elections. With Democrats gaining control of both chambers of Congress, lawmakers who campaigned on expanding public healthcare coverage will have greater opportunities to introduce legislation, conduct hearings and advance proposals that previously faced opposition from Republican congressional leadership. The article distinguishes between two major approaches. Medicare for All generally refers to a national single-payer system intended to provide comprehensive health coverage through a government-administered insurance program. A public option, by contrast, would allow eligible Americans to enroll in a publicly sponsored insurance plan while preserving private insurance alternatives. Japsen identifies newly elected Michigan Senator Abdul El-Sayed, an epidemiologist and former public health official, as a prominent supporter of Medicare for All. He also highlights Montana Democratic Representative-elect Sam Forstag, a labor union leader and former smokejumper who campaigned on allowing Americans to join Medicare with additional subsidies intended to make coverage more affordable for working households. Another example is Iowa Senator-elect Josh Turek, who advocated restoring Medicaid funding, protecting Affordable Care Act subsidies and eventually establishing a public insurance option. Turek specifically identified approximately 110,000 Iowans potentially affected by Medicaid reductions and 118,000 residents dependent on Affordable Care Act subsidies as populations he sought to protect. The article also discusses the broader Democratic effort to reverse healthcare provisions of the One Big Beautiful Bill Act, enacted in 2025. That legislation introduced additional Medicaid eligibility, work and administrative requirements projected to reduce federal Medicaid spending by hundreds of billions of dollars over the following decade, with significant changes scheduled to begin in January 2027. Democrats have additionally criticized the expiration of enhanced Affordable Care Act premium tax credits at the end of 2025, arguing that restoring those subsidies would help households afford private insurance purchased through federal and state marketplaces. Japsen places the debate within the history of American healthcare reform, noting that the Affordable Care Act expanded coverage through Medicaid and subsidized private insurance rather than creating a universal single-payer system. Medicare Advantage, which allows private insurers to administer Medicare benefits, illustrates another existing combination of government financing and private-sector participation. Although the election results give Democrats greater influence over healthcare legislation, significant obstacles remain. President Trump retains veto authority, Senate procedures can complicate passage of major bills, and Democratic lawmakers disagree over whether to prioritize incremental reforms or comprehensive restructuring. Supporters of public insurance expansion argue that it could improve affordability and reduce coverage gaps, while opponents raise concerns about federal spending, taxation, provider reimbursement and the consequences for private insurance markets. The article’s broader significance is that the election has reopened debate over the federal government’s role in healthcare, even though congressional control alone does not guarantee enactment of Medicare for All or a public option.

Hour 2

GLP-1 Drugs Beat Standard Prediabetes Treatment A November 4, 2026, Newsmax health article addresses preliminary research suggesting that GLP-1 medications, widely used to treat type 2 diabetes and obesity, may provide greater protection against progression from prediabetes to diabetes than metformin, a commonly prescribed and comparatively inexpensive medication. The findings come from an analysis presented in connection with the American Heart Association’s Scientific Sessions 2026, scheduled for November 6 through 9 in Chicago. Researchers examined electronic health records from 256,492 adults diagnosed with both prediabetes and obesity, using information collected from 104 healthcare institutions between 2010 and 2023. Participants had an average age of 52, and approximately 76% were women. Investigators compared outcomes among patients prescribed metformin with those receiving GLP-1-based medications, including semaglutide, tirzepatide, liraglutide and dulaglutide. To reduce the influence of differences between the groups, researchers matched patients according to characteristics such as age, existing medical conditions and other medications. Patients were followed for approximately three years on average. Compared with metformin users, patients receiving GLP-1 medications were approximately 1.5 times as likely to return from prediabetic blood glucose levels to the normal range. They also had a 31% lower relative risk of progressing to type 2 diabetes and a 41% lower relative risk of death from any cause. Additional findings suggested cardiovascular benefits, including 15% fewer heart attacks, 20% fewer strokes, 25% fewer heart failure events and 8% fewer cases of atrial fibrillation. Lead researcher Dr. Vinicius de Sousa Barzon Serra of the Mayo Clinic in Scottsdale, Arizona, suggested that the results could encourage physicians to consider GLP-1 medications earlier for selected patients with prediabetes, rather than reserving them primarily for established diabetes or obesity treatment. American Heart Association past president Dr. Robert Eckel noted that weight loss itself may explain some of the observed benefits because reducing excess weight can improve insulin sensitivity and cardiovascular risk factors. However, the study was observational rather than a randomized clinical trial, meaning it cannot establish that GLP-1 medications directly caused the differences in outcomes. Researchers relied on medical records and prescription information, which may not accurately reflect medication adherence, dosing or every relevant difference between patients. The analysis also grouped several medications together, preventing reliable conclusions about the comparative effectiveness of individual drugs. The findings were released as a scientific conference abstract and had not yet undergone the peer review required for publication as a full research paper. Serra emphasized that metformin remains an important first-line option because of its established safety record, affordability and extensive clinical experience. Dietary changes, physical activity and weight management also remain central to prediabetes treatment. The broader significance is the possibility that GLP-1 medications could play an expanded role in preventing diabetes and cardiovascular complications, although treatment decisions must account for cost, access, adverse effects and the need for stronger evidence from prospective clinical trials.

Why a US-funded vaccine trial on babies was cancelled in Guinea-Bissau In October 2026, a controversial United States-funded clinical trial involving newborn babies in Guinea-Bissau was formally cancelled after objections from international health organizations, researchers and officials in the West African country. The proposed study, developed by Danish researchers associated with the Bandim Health Project and the University of Southern Denmark, was intended to investigate whether administering the hepatitis B vaccine at birth affected overall infant health outcomes beyond protection against hepatitis B infection. Researchers planned to enroll approximately 14,000 newborns, randomly assigning half to receive the vaccine immediately after birth while the remaining infants would receive it at six weeks of age, consistent with Guinea-Bissau’s existing vaccination schedule. The project was expected to receive $1.6 million from the U.S. Centers for Disease Control and Prevention, with an additional $1.6 million from private funding sources. Supporters argued that the trial could provide evidence about possible nonspecific effects of vaccination, including interactions with other childhood immunizations and differences in overall health outcomes. However, the proposal encountered substantial criticism because hepatitis B vaccination at birth is already an established preventive intervention, particularly in countries with high rates of chronic hepatitis B infection. The World Health Organization warned in February that delaying vaccination in a randomized study could expose infants to preventable infections with potentially lifelong consequences, including chronic liver disease and liver cancer. Critics also questioned whether families could provide genuinely voluntary informed consent when participation offered a chance to receive a vaccine that was otherwise not routinely available at birth. The controversy intensified when a Danish university ethics committee approved a revised study protocol in October, prompting several committee members to resign over ethical concerns. Guinea-Bissau’s health minister, Quinhin Nantote, subsequently disputed reports that the national government had authorized the trial. On October 16, the country’s Council of Ministers formally reaffirmed its refusal to approve the project. Three days later, judicial police searched the Bandim Health Project’s offices and secured a supply of hepatitis B vaccines intended for the research. Lead researcher Christine Stabell Benn confirmed that the study had not begun and that none of the vaccines had been administered. On October 21, researcher Frederik Schaltz-Buchholzer publicly acknowledged that the project would not proceed because the necessary governmental authorization had not been obtained. The researchers maintained that their underlying scientific questions remained important, while critics argued that the study’s potential benefits did not justify the risks of delaying a proven intervention. Guinea-Bissau plans to introduce universal hepatitis B vaccination at birth in 2028, and international health organizations have offered assistance in accelerating implementation. The broader significance concerns the ethical requirements for international medical research, the authority of host countries to approve or reject foreign-funded studies, and the responsibilities of researchers when investigating established preventive treatments in populations with limited healthcare resources

Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!

Today’s Homeopathic Hit is Cadmium sulphuratum, or Cadmic Sulphate.

Boericke’s historical remedy picture centers on profound weakness, violent nausea and vomiting, stomach tenderness, marked chilliness, and a desire to remain still.

Download the  Information Sheet

Remember Friends, The Power to Heal is Yours!

The post Jonathan Emord, Trump Responds to Democrats, Iran War Election Impact, Progressive Party Divisions, Jefferson and Secession, Republican Democrat Accountability, Medicare for All Returns, Congressional Health Freedom Debate, GLP-1 Prediabetes Treatment, Guinea-Bissau Vaccine Trial Cancellation, Cadmium Sulphuratum, and MORE! appeared first on The Robert Scott Bell Show.

The post Phaseolus Nanus appeared first on The Robert Scott Bell Show.

Wednesday on The Robert Scott Bell Show:

Hour 1

Patients Who Ask Questions Have a Psychological Disorder, Medical Establishment Tells Doctors In a November 3, 2026, commentary published by Children’s Health Defense, clinical psychologist Roger McFillin criticizes the way some medical professionals are being encouraged to respond to patients who question conventional treatments, vaccination recommendations or information provided by healthcare institutions. His argument centers on an October 19 Medscape article titled Why Your Patient Trusts Unsupported Claims but Not You, part of a series examining deteriorating trust between physicians and patients. McFillin reports that the Medscape article cited a survey of more than 1,000 physicians, nearly all of whom said they had encountered patients influenced by medical misinformation during the preceding year. He challenges how misinformation is defined and argues that disagreements with established medical recommendations should not automatically be interpreted as evidence of irrational thinking. Particular attention is given to the psychological concept of selective skepticism, in which individuals reject evidence from certain sources while accepting less reliable claims that reinforce existing beliefs. McFillin also criticizes a communication technique known as psychological inoculation, which involves preparing patients to recognize and resist potentially misleading arguments before encountering them. He contends that these approaches can become tools of persuasion rather than opportunities for genuine discussion when physicians assume their conclusions are correct before considering patients’ concerns. Drawing on his experience in clinical psychology, he compares certain institutional communication practices to those used by organizations that discourage dissent, although these comparisons are his interpretation rather than a demonstrated characterization of the medical profession. The article expands into criticism of pharmaceutical-centered healthcare, arguing that modern medicine emphasizes chronic disease management and prescriptions while insufficiently addressing underlying causes of illness. McFillin references the 1910 Flexner Report and the subsequent transformation of American medical education as historical developments that he believes contributed to this emphasis. He then examines programs that offer vaccinations to children while they are already under anesthesia for unrelated medical procedures. At Children’s Hospital of Philadelphia, he identifies an initiative offering influenza vaccination during sedation, and he cites a Colorado hospital program that has vaccinated more than 18,000 children under deep sedation or general anesthesia. He acknowledges that parental consent is obtained but questions whether the stressful circumstances surrounding surgery provide an appropriate environment for informed decision-making. He also raises concerns about distinguishing postoperative complications from vaccine reactions when interventions occur close together. Importantly, the Medscape discussion of misinformation and patient communication does not establish that asking medical questions is itself a recognized psychological disorder, and the article does not identify a formal psychiatric diagnosis based simply on questioning a physician. McFillin’s headline expresses his criticism of how patient skepticism may be interpreted, rather than documenting a new medical classification. His central argument is that informed consent requires meaningful opportunities to question recommendations, review evidence, understand risks and consider alternatives without being dismissed or pressured into agreement. The broader issue concerns how healthcare professionals can address demonstrably inaccurate information while preserving patient autonomy, respectful communication and trust.

Soil Plastic in Your Food? Study Exposes New Microplastic Risk In an October 29, 2026, article, the Alliance for Natural Health USA examines emerging research suggesting that microplastic contamination in agricultural soils may disrupt plant growth, soil biology and potentially the nutritional systems supporting human health. The report focuses on a controlled greenhouse experiment involving barley plants grown for 60 days in specialized containers designed to study interactions between roots and surrounding soil. Researchers introduced polyethylene or polyvinyl chloride microplastics at concentrations representing 2% or 4% of dry soil mass, with three experimental replicates for each treatment. The higher polyethylene concentration and both PVC treatments reduced photosynthetic activity by approximately 18% to 25%, indicating that substantial plastic contamination can interfere with a plant’s ability to convert sunlight into chemical energy. Researchers also observed changes in antioxidant enzyme activity, soil nutrient availability, enzyme distribution and the structure of bacterial and fungal communities surrounding the roots. Some biological measurements increased while others declined, demonstrating that microplastics can produce complex effects rather than a single uniform response. The study does not establish that ordinary agricultural soils contain comparable plastic concentrations or that the experimental changes necessarily translate into reduced nutritional quality in commercially grown food. Nevertheless, ANH argues that the findings justify further investigation into agricultural plastic pollution. The organization cites Food and Agriculture Organization estimates that agricultural production used approximately 12.5 million metric tons of plastic in 2019, with an additional 37.3 million metric tons used in food packaging. These figures represent plastic consumption, not the quantity entering farmland, but they illustrate the scale of materials potentially contributing to environmental contamination. The article also reviews research identifying microplastics and nanoplastics in drinking water, human blood, lungs and reproductive tissues. A 2024 bottled-water study estimated an average of 240,000 plastic particles per liter across three tested brands, most of them nanoplastics. ANH highlights a separate 2024 study involving 257 patients who underwent surgery to remove carotid artery plaque. During approximately three years of follow-up, heart attack, stroke or death occurred in 20% of patients with detectable plastic particles in their arterial plaque, compared with 7.5% of patients without detectable particles. This observational association does not establish that the particles caused those outcomes. Additional research involving humans and laboratory animals has raised questions about possible reproductive, digestive and respiratory effects, although the extent of harm from typical environmental exposure remains uncertain. ANH recommends reducing avoidable exposure through drinking-water filtration, using glass or ceramic containers for heating food, minimizing plastic kitchen utensils and reducing household dust. The organization also calls for agricultural policies that improve plastic waste recovery, reduce contamination from farming materials and support further research using environmentally realistic exposure levels. The broader significance is that plastic pollution may affect human health both through direct exposure and through changes to the biological systems involved in food production, making soil protection an important component of environmental and preventive health policy.

The Epistemic Corruption of Biomedical Science In a November 1, 2026, article published by Activist Post and attributed to Brownstone Institute contributor Josh Guetzkow, the author argues that commercial interests have increasingly influenced biomedical research, regulatory decisions, medical publishing and public health communication. The essay is an abbreviated version of a chapter prepared for the book Fear and Loathing in the Pandemic: Propaganda and Misinformation during Covid-19, edited by Colin Alexander. Guetzkow uses the concept of epistemic corruption, developed in scholarship examining the pharmaceutical industry, to describe circumstances in which institutions responsible for producing reliable scientific knowledge become influenced by financial, professional or organizational incentives that conflict with independent inquiry. He draws on the work of science studies scholars Thomas Kuhn, Thomas Gieryn and Sergio Sismondo to argue that scientific consensus can be shaped not only by evidence but also by institutional authority and control over research funding, publication and professional recognition. Particular attention is given to industry involvement in clinical trial design, data analysis, medical journal publication and regulatory oversight. Guetzkow describes ghost management, in which pharmaceutical companies influence research and publication while academic researchers appear as independent authors. He also highlights financial relationships involving peer reviewers, citing research reporting that nearly 60% of reviewers at leading medical journals received payments from drug or medical device manufacturers totaling approximately $1.06 billion between 2020 and 2022. These financial relationships raise potential conflicts of interest, although payments alone do not establish that individual reviewers manipulated scientific conclusions. The article examines selective publication of antidepressant trials, arguing that studies with unfavorable results were less likely to appear in medical journals or were presented in ways that emphasized positive findings. Guetzkow then applies his framework to COVID-19 vaccine development and public communication. He criticizes the compressed development timetable under Operation Warp Speed, questions aspects of clinical trial design and manufacturing oversight, and alleges that adverse-event information received insufficient attention. He references individual trial participants who reported serious medical problems and argues that their experiences were inadequately represented in published research. The essay also discusses the difference between relative and absolute risk reduction, noting that vaccine trial headlines frequently emphasized relative reductions in symptomatic disease without equivalent attention to absolute differences between trial groups. These measures answer different statistical questions, and neither is inherently invalid when presented with appropriate context. Guetzkow further argues that scientists questioning official pandemic policies experienced professional retaliation, publication barriers and social media restrictions. Several of his broader conclusions, including claims of coordinated suppression and the characterization of COVID-19 vaccine science as a propaganda system, remain contested interpretations rather than conclusions established by the article alone. His proposed remedies include stronger conflict-of-interest restrictions, greater clinical trial transparency, independent regulatory oversight and protections for scientific dissent. The central issue is how biomedical institutions can maintain public trust when commercial relationships and institutional incentives create real or perceived conflicts between scientific independence, public health responsibilities and pharmaceutical business interests.

Omega-3s May Improve Survival in Advanced Cancer An October 30, 2026, health report examines findings from a major clinical trial suggesting that high doses of the omega-3 fatty acid eicosapentaenoic acid, or EPA, may improve long-term survival among certain patients with advanced colorectal cancer. The research, presented at the European Society for Medical Oncology Congress 2026 in Madrid, involved 418 patients at 13 surgical centers in the United Kingdom who were scheduled to undergo operations to remove colorectal cancer that had spread to their livers. In the randomized, double-blind, placebo-controlled phase 3 EMT2 trial, participants received either 4 grams daily of high-purity prescription EPA, known as icosapent ethyl, or a mineral oil placebo. Treatment began before surgery and was intended to continue for two to four years, including after disease progression. Researchers reported that estimated five-year overall survival reached 62% among patients receiving EPA, compared with 45.1% among those receiving placebo. This represents a difference of approximately 17 percentage points, with the statistical analysis indicating a 32% lower hazard of death in the EPA group during the observation period. However, the study produced an important distinction between overall survival and cancer progression. Median progression-free survival was 13.5 months among EPA recipients and 12.9 months among placebo recipients, a difference that was not statistically significant. Consequently, the trial did not achieve its primary endpoint of demonstrating that EPA meaningfully delayed cancer recurrence or progression. Lead investigator Professor Mark Hull of the University of Leeds suggested that the survival findings might reflect effects on the body’s response to cancer rather than a direct ability to prevent tumor growth. One possible mechanism involves cancer-related cachexia, a condition associated with inflammation, muscle loss, reduced appetite, fatigue and declining physical function. EPA has been investigated for its potential effects on inflammatory processes, although the trial did not establish which biological mechanism accounted for the observed survival difference. Researchers reported that EPA was generally well tolerated, with no significant increase in adverse events, bleeding or atrial fibrillation compared with placebo. Quality-of-life measurements also showed no apparent disadvantage. The survival findings remained consistent in several additional analyses, including adjustments for differences in diabetes prevalence between the treatment groups. Independent oncology expert Dr. Chiara Cremolini of the University of Pisa described the results as promising but emphasized that the difference between overall survival and progression-free survival requires careful interpretation. She also cautioned that additional trials are needed before EPA can be recommended routinely for patients undergoing surgery for colorectal cancer liver metastases. The findings were presented at a scientific conference and had not yet been published as a completed peer-reviewed trial report. They also concern a specific population receiving a prescription-strength, high-purity EPA preparation, not patients with every form of advanced cancer or individuals taking ordinary over-the-counter fish oil supplements. The broader significance is that nutritional compounds with established biological activity may have useful roles alongside conventional cancer treatment, but promising survival results require independent confirmation before becoming standard clinical practice.

Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!

Today’s Homeopathic Hit is Phaseolus nanus, or Dwarf-bean.

In Boericke’s materia medica, its most pronounced traditional picture involves fearful heart palpitations, a rapid or weak pulse, slow sighing breathing, and associated head and eye symptoms.

Download the  Information Sheet

Hour 2

More Than Half of Americans Live with Neurological Conditions In an article published by Activist Post and originally written by Dr. Joseph Mercola, new research is examined showing that more than half of Americans are living with at least one condition affecting the nervous system, raising concerns about the growing burden of neurological disease, disability and healthcare costs. The central findings come from a study published in JAMA Neurology in November 2025, conducted by researchers affiliated with the American Academy of Neurology, the Institute for Health Metrics and Evaluation and several American universities. Using data from the Global Burden of Disease 2021 project, researchers estimated that approximately 54.2% of the United States population, representing 180.3 million people, had at least one of 36 neurological conditions. These included tension-type headaches, migraines, diabetic neuropathy, stroke, Alzheimer’s disease and other disorders affecting the brain, spinal cord and peripheral nerves. Tension-type headaches were the most common, affecting approximately 121.9 million Americans, followed by migraines at 57.7 million and diabetic neuropathy at 17.1 million. Approximately 6.3 million people were living with the effects of stroke, while 4.9 million had Alzheimer’s disease or other dementias. Collectively, neurological conditions accounted for an estimated 16.6 million disability-adjusted life years, representing approximately 13% of the nation’s total health loss in 2021. The study found substantial geographic differences, with Southern states such as Mississippi, Alabama and Louisiana experiencing greater neurological disease burdens than Northeastern states including Massachusetts, New York and New Jersey. Researchers attributed some of these differences to socioeconomic conditions, rural healthcare access and established risk factors for cardiovascular and neurological disease. Although the total number of affected Americans has increased substantially since 1990, the age-adjusted prevalence rate changed by only 0.2%, indicating that population growth and aging explain much of the increase rather than a dramatic rise in individual risk. During the same period, age-adjusted neurological mortality declined by 14.6%, while years lived with disability increased by 9.8%, reflecting improved survival alongside greater long-term care needs. Mercola also examines a separate study published in The Lancet Public Health estimating that worldwide direct healthcare spending on brain-related disorders reached $1.7 trillion in 2019, including approximately $894 billion for neurological conditions and $830 billion for mental health disorders. Stroke accounted for more than $330 billion in spending, followed by Alzheimer’s disease and other dementias at approximately $205 billion. The article highlights substantial international inequalities, with high-income countries accounting for 78% of global brain-health expenditures despite representing less than 20% of the associated disease burden. Beyond the research findings, Mercola argues that mitochondrial dysfunction may contribute to neurological disease and recommends reducing dietary linoleic acid, improving intestinal health and limiting exposure to plastics and electromagnetic fields. These recommendations represent the author’s interpretation and should be distinguished from the findings of the cited neurological prevalence study, which did not establish those exposures as causes of the reported disease burden or demonstrate that Mercola’s proposed interventions prevent neurological disorders. The article’s broader significance is the scale of neurological illness in the United States, the growing demand for long-term disability services and the need for research, prevention, earlier diagnosis and improved access to specialized neurological care.

Special Guest: Inesa Ponomariovaite

Inesa Ponomariovaite, the founder of Nesa’s Hemp, is a visionary leader with a profound commitment to holistic health. Growing up in a working-class family in Lithuania, Inesa began working at the age of 10 to support her family, eventually taking on the responsibility of caring for her siblings. As a young adult, she moved to the United States, where she faced severe health challenges and domestic violence, which left her hospitalized and homeless. Demonstrating remarkable resilience, Inesa rebuilt her life through sheer determination and hard work. Her journey to health led her to transition from relying on pharmaceuticals to embracing natural foods and exercise, ultimately restoring her well-being.

Inesa’s passion for holistic health was further ignited by her mother’s cancer diagnosis, prompting her to explore the potential of CBD. Through extensive research and collaboration with experts worldwide, she discovered that many existing CBD products were of substandard quality. Determined to create a superior product, Inesa founded Nesa’s Hemp, which produces the world’s first full-spectrum CBDa Hemp Oil. Her products are meticulously crafted to be 100% natural and free from chemicals, solvents, and heavy metals. Inesa’s mission is to change the world by helping people harness the healing power of nature, promoting well-being in body, mind and spirit.

Congress’s New CBD Pathway: The Promise and the Peril Congress is considering legislation that could preserve access to hemp-derived CBD supplements while creating new regulatory authority that the Alliance for Natural Health USA (ANH-USA) warns could ultimately restrict many of the same products the legislation is intended to protect. Federal restrictions enacted in November 2025 are scheduled to take effect on November 12, 2026, establishing a limit of 0.4 milligrams of THC per container that could effectively eliminate numerous full-spectrum CBD oils and other hemp products containing naturally occurring trace amounts of THC. A Senate funding proposal would postpone most of these restrictions until December 11, providing an additional 29 days for lawmakers to negotiate, although the extension was not yet law when the article was published. The bipartisan Lawful Hemp Protection Act, introduced by Representatives Andy Barr and Angie Craig, would eliminate the impending restrictions, increase the allowable THC concentration in hemp plants from 0.3% to 1% by dry weight, exclude synthetic or chemically altered cannabinoids, and establish a legal pathway for hemp-derived cannabinoids to be marketed as dietary supplements. However, ANH-USA raises concerns that the legislation would authorize the FDA to establish maximum allowable quantities for every cannabinoid in a product, including non-intoxicating compounds such as CBD, CBG, CBN, and CBC. The organization argues that excessively restrictive limits could make otherwise legal supplements commercially impractical or unavailable. The proposal would also prohibit structure/function claims on product labels, preventing manufacturers from describing how cannabinoids affect normal bodily functions even when those statements are supported by evidence. ANH-USA emphasizes the importance of full-spectrum hemp products, which contain multiple cannabinoids and terpenes that may interact through the proposed entourage effect, and warns that restrictive THC limits could favor isolated CBD products over whole-plant formulations. The organization favors the alternative Cannabinoid Safety and Regulation Act, which it says would focus regulatory restrictions on intoxicating cannabinoids while preserving access to non-intoxicating supplements and allowing substantiated structure/function claims. ANH-USA is urging Congress to preserve the proposed temporary extension, revise the Lawful Hemp Protection Act to limit FDA authority over non-intoxicating cannabinoids, and establish safety standards addressing synthetic intoxicants, adulteration, misleading marketing, and sales to minors without broadly restricting responsibly manufactured hemp products.

A $28 billion hemp THC industry is fighting to save itself from a looming federal ban The multibillion-dollar American hemp-derived THC industry faces sweeping federal restrictions scheduled to take effect in November 2026, threatening businesses that manufacture and sell hemp-based gummies, beverages, oils, and other cannabinoid products. The restrictions originated in legislation passed in November 2025 to end the federal government shutdown and would substantially narrow the legal definition of hemp established under the 2018 Farm Bill. That earlier law legalized hemp containing less than 0.3% delta-9 THC by dry weight, allowing companies to develop a market for products containing intoxicating cannabinoids, including delta-8 THC and other hemp-derived compounds. The newer restrictions address total THC content in finished products and synthetically derived cannabinoids, potentially eliminating many products currently sold legally. Supporters of the restrictions, including Senator Mitch McConnell, argue that the changes are necessary to prevent intoxicating products from reaching children and to close regulatory loopholes that allowed THC products to be sold without the oversight applied to state-regulated marijuana. Hemp businesses and industry organizations counter that the legislation goes too far, threatening farmers, manufacturers, retailers, jobs, and tax revenue while potentially driving consumers toward unregulated markets. Kentucky companies such as Cornbread Hemp warn that products containing even relatively small amounts of naturally occurring THC could become prohibited. Senator Rand Paul and other lawmakers have supported efforts to preserve access through alternative legislation emphasizing age restrictions, independent laboratory testing, manufacturing standards, and clearer distinctions between intoxicating and nonintoxicating products. Some industrial hemp producers, particularly those specializing in fiber, grain, and seed products, emphasize that the restrictions do not prohibit all hemp cultivation or uses. The dispute centers on whether Congress should prohibit broad categories of hemp-derived cannabinoid products or establish a comprehensive regulatory system that addresses product safety, youth access, labeling, and manufacturing practices while allowing the industry to continue operating.

Question of The Day!

Hi Guys-
I’ve asked questions about this before, but not in this way…
I have Post Herpetic Neuralgia- the super-painful, lingering peripheral nerve pain after having Shingles.
Shingles has been over for five years now, but the pain is excruciating and all that works is that awful pain medication we all want to avoid like the plague.
I’ve rebuilt my immunity…never took the jabs, but…
What do you recommend that aids in the healing of nerves? Vitamin B? Silver hydrosol? I would covet any help you may have…
Amynfam

Remember Friends, The Power to Heal is Yours!

The post Questioning Patients Pathologized, Soil Microplastics Food Risks, Biomedical Science Integrity, Omega-3 Cancer Survival, Phaseolus Nanus, Neurological Conditions Surge, Inesa Ponomariovaite, Nesa’s Hemp, CBDa, Shingles Nerve Pain Relief, and MORE! appeared first on The Robert Scott Bell Show.

The post Petroselinum Sativum appeared first on The Robert Scott Bell Show.

Tuesday on The Robert Scott Bell Show:

Hour 1

What Is Health For? In an October 31, 2026, essay published by Sensible Medicine, Kirsten Balin, a family nurse practitioner working in emergency medicine and private practice in rural Oregon, challenges conventional assumptions about what it means to be healthy and questions whether modern medicine has become overly focused on measurements, risk factors and the pursuit of ideal laboratory results. Balin argues that health should not be defined exclusively by the absence of disease, the number of medications someone takes or whether measurements such as cholesterol, blood pressure, blood glucose and body weight fall within recommended ranges. Drawing on her clinical experience, she describes older patients living with arthritis and other chronic conditions who nevertheless consider themselves healthy because they remain capable of hunting, gardening, traveling, working and spending meaningful time with their grandchildren. She contrasts these individuals with younger patients whose medical tests appear normal but who remain convinced that an undiscovered condition must explain their symptoms. These examples illustrate her central argument that medical measurements do not necessarily capture a person’s functional abilities, quality of life or overall well-being. Balin acknowledges that preventive medicine plays an essential role in identifying serious conditions before symptoms develop, citing dangerously elevated blood pressure, uncontrolled diabetes and early-stage cancer as examples of problems that require attention even when patients feel well. However, she cautions against interpreting every abnormal laboratory value, incidental imaging finding or ordinary physical discomfort as evidence of illness requiring further investigation or treatment. She observes that aging naturally brings changes in physical performance, sleep and comfort, and that the human body rarely conforms perfectly to standardized medical expectations. Balin also reflects on her own experience, describing occasional sleepless nights, fluctuations in exercise performance and the temptation to monitor increasingly detailed fitness measurements. Rather than continually attempting to optimize those numbers, she places greater importance on her ability to work, exercise, travel and perform everyday activities. The essay questions whether medicine has adequately established a point at which a person can reasonably be considered healthy enough, particularly when additional testing or treatment can almost always identify another potential risk to reduce. Balin emphasizes that medical measurements should serve meaningful patient goals rather than become goals in themselves. Lowering cholesterol or blood pressure, for example, matters because it may help preserve the ability to participate in valued activities and avoid future illness, not simply because achieving a particular number represents success. Her perspective does not reject medical screening, preventive care or evidence-based treatment. Instead, it advocates balancing those interventions against the patient’s circumstances, priorities and functional well-being. The broader message is that health should support a fulfilling life rather than become an endless project of medical optimization. Balin concludes that a realistic definition of health must accommodate imperfection, aging and ordinary physical limitations while recognizing that the ultimate purpose of maintaining health is to enable people to live their lives.

Special Guest: Kevin Stillwagon

Dr. Kevin Stillwagon is a retired chiropractor, former commercial airline captain, author, inventor, and longtime advocate for health freedom and informed medical consent. Raised in a chiropractic family, he graduated as co-valedictorian from Palmer College of Chiropractic in 1980 and practiced in Pennsylvania and Florida. In 1984, he authored The Silent Killers, a book examining vaccination and medical freedom, and later developed and patented a computerized thermographic imaging device.

In 1987, Dr. Stillwagon began a commercial airline career that spanned more than three decades, eventually serving as a captain for Northwest and Delta Air Lines. He retired in 2020 after refusing to comply with his airline’s face-mask requirements, an experience that intensified his public advocacy against medical mandates. A board member of US Freedom Flyers, he has become an outspoken commentator on vaccine safety, immune system function, individual medical choice, and health freedom. Through public speaking, interviews, educational videos, and his Substack newsletter, Dr. Stillwagon continues to challenge conventional public health policies and advocate for bodily autonomy and informed consent.

AI Health Advice: 6 In 10 Users Would Believe A Chatbot Over Their Doctor In an October 30, 2026, article published by StudyFinds, a new survey raises concerns about the growing willingness of Americans to trust artificial intelligence for medical advice, even when chatbot recommendations conflict with guidance from healthcare professionals. The survey, conducted by Talker Research between June 18 and July 6, 2026, questioned 2,000 adults, including 1,000 millennial parents and 1,000 respondents from the general population. Half of each group reported using artificial intelligence for health-related questions. Among respondents who used AI for health purposes, 60% said they would believe information generated by a chatbot even if it contradicted advice from a healthcare provider, while 63% acknowledged having followed AI health recommendations without confirming them with a medical professional. The findings also revealed that 58% of millennial parents who used AI for health questions had acted on chatbot advice concerning their children without consulting a healthcare provider. Convenience was a major motivation, with 37% citing ease of access, 31% identifying faster answers and 30% seeking reassurance. On average, respondents using AI for health purposes reported asking approximately nine medical questions each week. The survey also identified behaviors that could undermine the reliability of the answers received. Fifty-three percent admitted rewording questions after receiving an answer they disliked, while 42% said they had misrepresented who a medical question concerned because of privacy concerns. Additionally, 78% did not realize that the wording of their questions could affect chatbot responses. Nearly half of AI users reported acting on information before discovering that it did not fully apply to their circumstances, and 59% subsequently recognized that advice they received was not entirely appropriate for their situation. The survey also identified misconceptions about artificial intelligence, including the belief among some respondents that chatbots exclusively consult trustworthy medical sources or automatically incorporate a patient’s medical history without that information being supplied. Dr. Maggie Williams, medical director of virtual primary care at MD Live by Evernorth, emphasized that clinicians can identify missing details, ask follow-up questions and interpret symptoms within the context of a patient’s individual medical history. Importantly, the survey was commissioned by MD Live, a virtual healthcare provider with a commercial interest in promoting clinician oversight, and its findings rely on self-reported attitudes rather than independently observed medical decisions. The results do not establish that chatbot recommendations are generally less accurate than physicians’ advice or that the reported behavior caused measurable harm. Instead, they demonstrate the extent to which some AI users are prepared to rely on automated medical information without independent verification. The broader issue concerns how artificial intelligence can improve access to understandable health information while avoiding misplaced confidence, incomplete clinical assessments and potentially inappropriate treatment decisions.

Martha Stewart apologizes for dressing up as homeless person for Halloween In a November 2, 2026, article published by Not the Bee, writer Holly Ash examines the controversy surrounding lifestyle entrepreneur Martha Stewart’s decision to dress as a homeless person for Halloween and her subsequent public apologies following criticism on social media. Stewart, 85, posted photographs on Instagram on October 31 showing herself wearing distressed jeans, a worn sweater, a knit cap and dark makeup intended to resemble dirt on her face. She also held a sign asking for food and assistance, portraying someone experiencing homelessness. The photographs appeared in a social media post that also promoted her candle collection, a detail that contributed to criticism from people who believed the depiction trivialized poverty while simultaneously advertising commercial products. Critics described the costume as insensitive and disconnected from the circumstances of people struggling with housing insecurity, particularly during a period of financial hardship for many American households. Stewart removed the original photographs and initially issued a statement to Page Six explaining that her intention had been to draw attention to homelessness rather than ridicule people experiencing it. She emphasized that homelessness remains a serious national problem and stated that she has supported charitable organizations working to address it. Her initial explanation did not satisfy all critics, prompting a second statement in which she acknowledged that her first response had been inadequate, described the costume as insensitive and apologized. The Not the Bee article approaches the controversy from a distinctly different perspective than reports emphasizing the criticism of Stewart. Ash characterizes the backlash as an example of excessive social media outrage and argues that Stewart should not have felt compelled to apologize for a Halloween costume. The commentary uses sarcasm to question whether public criticism of the outfit meaningfully advances efforts to address homelessness. That perspective contrasts with critics who argue that presenting poverty as entertainment can diminish the dignity of people experiencing genuine hardship, particularly when the portrayal comes from a wealthy public figure. Other commenters defended Stewart, suggesting that her costume was consistent with longstanding Halloween traditions and that attention would be better directed toward practical assistance for people without housing. The controversy therefore involves competing interpretations of personal expression, public sensitivity and the responsibilities of celebrities with large audiences. There is no indication that Stewart faced legal consequences or that her costume violated any law. The central dispute concerns social expectations, the influence of online criticism and whether public apologies reflect genuine accountability or pressure to conform to prevailing attitudes. The broader significance is how quickly social media controversies can transform an individual act of expression into a national discussion about wealth, poverty, humor and cultural boundaries.

Hour 2

Biden’s COVID Censorship Machinery ‘Built to Last,’ New Documents Show In a November 2, 2026, investigation published by Children’s Health Defense, journalist Michael Nevradakis examines newly publicized internal Biden administration documents describing efforts by former U.S. Surgeon General Vivek Murthy’s office to influence how social media companies handled COVID-19 and other health-related information. The documents, originally obtained through a Freedom of Information Act request filed by the watchdog organization Protect the Public’s Trust and subsequently reported by the Daily Caller News Foundation, reveal that Murthy’s advisers developed an extensive communications strategy involving technology companies, healthcare professionals, universities, businesses and national news organizations. A central component was a specialized misinformation team that discussed applying maximum pressure and maintaining regular engagement with social media platforms. According to a May 2021 email from policy adviser Daniel Tartakovsky, the administration’s concerns extended beyond COVID-19 to medical and health misinformation more generally, particularly its influence on younger people. The article argues that this broader focus demonstrates an intention to establish a continuing government role in shaping online health discussions. By July 2021, Murthy’s office was preparing a formal advisory on health misinformation and developing plans for meetings with researchers and technology executives. The strategy included engaging prominent media outlets, working with medical professionals and educators, and exploring celebrity partnerships to promote approved public health messages. Nevradakis also highlights internal communications suggesting that officials wanted platforms to restrict certain vaccine-related material even when it contained factually accurate information presented without context considered necessary by public health authorities. Additional talking points prepared for Murthy encouraged support for workplace vaccination requirements and advised him to avoid emphasizing concerns about vaccine safety or the regulatory process. Critics interviewed for the article, including Sayer Ji, Naomi Wolf and attorney Greg Glaser, argue that the documents demonstrate inappropriate government pressure on private platforms and raise serious First Amendment questions. They contend that government officials should not use their authority to discourage lawful criticism of medical policies or scientific conclusions. The administration’s stated rationale was that misleading health information could contribute to harmful medical decisions and that cooperation with platforms would help the public access reliable scientific guidance. The legal distinction between government persuasion and unconstitutional coercion remains important: federal officials may communicate with private companies, but their conduct can raise constitutional concerns when pressure becomes sufficiently coercive or effectively directs censorship. The documents establish the existence of coordinated messaging and platform engagement, although they do not independently prove that every resulting moderation decision was compelled by government officials or that a permanent censorship system was successfully established. The broader controversy concerns transparency, government influence over private communications platforms and the protection of public debate during health emergencies.

Americans Are Lying to Their Doctors to Get Antibiotics—and That’s Great News for Superbugs In a November 2, 2026, Gizmodo article, science journalist Ed Cara examines new research indicating that a substantial proportion of American adults have deliberately misrepresented their symptoms to healthcare providers in an effort to obtain antibiotic prescriptions. The study, conducted by researchers from the University of Utah and other institutions and published in JAMA Network Open, surveyed approximately 1,000 adults through an online research panel organized by market research company Dynata. Researchers used demographic quotas covering age, gender and geographic region to approximate the broader United States adult population. Approximately 28% of respondents acknowledged having misrepresented symptoms at least once to obtain antibiotics. Among those admitting this behavior, 40% reported exaggerating the severity or duration of an illness, 7% reported inventing symptoms, and approximately 53% reported using both approaches. Participants identified several motivations, including believing that antibiotics would help them recover, wanting to return to work or other responsibilities more quickly, and seeking greater control over medical treatment decisions. Researchers found that younger adults, particularly those ages 18 through 33, were more likely to report this behavior. Other associated factors included believing that physicians did not take their symptoms seriously and doubting the seriousness of antibiotic resistance. The findings raise concerns because antibiotics are effective against susceptible bacterial infections but generally provide no benefit for viral illnesses such as the common cold. Unnecessary antibiotic use exposes patients to potential adverse effects while contributing to selective pressure that allows resistant bacteria to survive and multiply. These resistant organisms can subsequently spread within communities and healthcare facilities, making infections more difficult and expensive to treat. The article references recent Centers for Disease Control and Prevention estimates indicating that antimicrobial-resistant infections cause approximately 50,000 deaths annually in the United States. Antibiotic exposure can also disrupt beneficial intestinal bacteria and increase the risk of complications such as Clostridioides difficile infection, which can cause severe diarrhea and potentially life-threatening illness. Researchers emphasize that inappropriate prescribing cannot be attributed solely to patients, since clinicians may prescribe antibiotics unnecessarily because of diagnostic uncertainty, time pressures or perceived patient expectations. The survey also has limitations because it relies on participants accurately recalling and admitting past behavior rather than directly observing medical consultations. Its findings establish reported patterns of deception, not the number of unnecessary prescriptions actually issued or the proportion of resistant infections caused by those interactions. The researchers recommend improved communication between patients and clinicians, clearer explanations of when antibiotics are useful and continued antimicrobial stewardship efforts. The broader significance is that preserving the effectiveness of antibiotics requires responsible decisions by both prescribers and patients, particularly as resistance increasingly threatens routine medical treatment.

Company Hired to Collect COVID Vaccine Injury Reports Warned CDC: ‘Too Many to Process’ In a November 2, 2026, article republished by Children’s Health Defense from the Brownstone Institute, author Jeffrey A. Tucker criticizes the Centers for Disease Control and Prevention’s handling of early COVID-19 vaccine safety reports, arguing that federal officials failed to respond adequately when a government contractor warned that incoming adverse-event reports had exceeded its processing capacity. The central document is a January 15, 2021, memorandum from General Dynamics Information Technology, which had been contracted to help process submissions to the Vaccine Adverse Event Reporting System, commonly known as VAERS. The company informed the CDC that the number of incoming COVID-19 vaccine reports had substantially exceeded its anticipated maximum of 1,000 per day, preventing it from meeting established deadlines for data processing, telephone inquiries and clinical follow-up. Tucker interprets the warning as evidence that federal officials should have immediately reconsidered the vaccination campaign and publicly investigated the unusually large volume of reports. He contrasts the contractor’s concerns with a CDC analysis published in the February 19, 2021, edition of the Morbidity and Mortality Weekly Report. That analysis, led by epidemiologist Julianne Gee, examined 6,994 adverse-event reports received during the initial vaccination period from December 14, 2020, through January 13, 2021. The CDC described the preliminary safety findings as generally reassuring and reported that most submitted adverse events were classified as nonserious. Tucker questions whether this conclusion adequately reflected the larger volume of reports accumulating in the surveillance system by the publication date. He also challenges the agency’s interpretation of reported deaths and serious adverse events, arguing that the public should have received stronger warnings while investigators examined potential safety signals. An essential distinction is that VAERS accepts reports of medical events occurring after vaccination without requiring proof that the vaccine caused them. Reports can identify patterns requiring investigation, but their volume alone cannot establish the frequency of vaccine-caused injuries, determine causation or demonstrate that a product should be withdrawn. Processing delays are nevertheless relevant because they can slow the evaluation of possible safety signals and reduce the timeliness of public reporting. Tucker additionally criticizes liability protections available to vaccine manufacturers under the Public Readiness and Emergency Preparedness Act, arguing that these arrangements weaken accountability for potential injuries. He contends that political, institutional and financial pressures discouraged officials from acknowledging safety concerns during the initial vaccine rollout. Those claims reflect the author’s interpretation of the documents rather than independently established findings of deliberate concealment. The memorandum documents a genuine operational problem, but it does not by itself establish that the CDC possessed evidence of widespread vaccine-caused injuries or intentionally suppressed confirmed adverse reactions. The article’s broader significance concerns the capacity of federal safety surveillance systems during mass vaccination campaigns, the transparency of government communications and the distinction between receiving adverse-event reports and establishing scientifically supported conclusions about medical product safety.

Common diabetes medications may trigger side effects that require even more drugs to fix: study In a November 1, 2026, New York Post report, new research published in BMC Medicine examines how medications commonly prescribed to people with type 2 diabetes may contribute to additional prescriptions intended to treat side effects of the original drugs. Researchers analyzed two large healthcare databases containing records from more than 387,000 individuals with type 2 diabetes, focusing on a phenomenon known as a prescribing cascade. A prescribing cascade occurs when an adverse reaction to one medication is interpreted as a separate medical condition, prompting a clinician to prescribe another drug rather than recognizing and addressing the original cause. The investigators evaluated twelve combinations of medications and identified seven patterns consistent with potential prescribing cascades. Among the drugs examined were sodium-glucose cotransporter-2 inhibitors, commonly called SGLT2 inhibitors, which lower blood sugar by encouraging the kidneys to remove glucose through urine. These medications can provide important benefits for certain patients, including reducing the risk of heart failure and slowing progression of kidney disease, but their effects on urinary glucose and fluid balance can also contribute to adverse reactions. Researchers found that patients beginning SGLT2 inhibitors were more likely to subsequently receive antibiotics, antifungal medications or drugs used to treat overactive bladder symptoms. Increased glucose in urine can encourage genital fungal infections, while changes in urination patterns may be mistaken for an unrelated bladder disorder. Another medication class, thiazolidinediones, improves insulin sensitivity but can cause fluid retention, swelling and weight gain. The study identified patterns in which patients receiving these drugs were subsequently prescribed loop diuretics to reduce fluid accumulation. Researchers also examined medications frequently used alongside diabetes treatment, including statins and calcium channel blockers. Statins were associated with subsequent prescriptions for certain bladder medications and sleep aids, while calcium channel blockers were followed by diuretics potentially intended to address lower-extremity swelling. The findings are particularly relevant for older adults, who often manage several chronic conditions and may already take multiple medications. Adding drugs can increase treatment complexity, financial costs, adverse interactions and the risk of additional side effects. However, the observational study cannot establish that every subsequent prescription resulted from a medication-induced adverse reaction. Patients with diabetes frequently have overlapping medical conditions that independently justify additional treatment, and some prescriptions may have been clinically appropriate. Researchers emphasize that recognizing possible prescribing cascades could help clinicians review existing medications, adjust dosages or consider alternatives before adding another drug. The study does not suggest that patients should discontinue diabetes medications without medical supervision, particularly when those drugs provide substantial cardiovascular, kidney or metabolic benefits. Its broader message is that healthcare providers should routinely reassess medication lists, investigate new symptoms as possible adverse reactions and avoid unnecessary prescribing when modifying an existing treatment could resolve the problem.

Welcome back to another “Homeopathic” episode on The Robert Scott Bell Show!

Today’s Homeopathic Hit is Petroselinum sativum, or Parsley.

Boericke identifies a distinctive urinary picture: sudden, compelling urges to urinate, with burning, tingling, biting, and itching felt deep along the urethra.

Download the  Information Sheet

Remember Friends, The Power to Heal is Yours!

The post Rethinking Health’s Purpose, Dr. Kevin Stillwagon, Lines In the Sky, Lear Jet Disaster, AI Doctor Health Advice, Martha Stewart Homeless Halloween, Biden COVID Censorship Revelations, Antibiotic Misuse, Vaccine Injury Reporting Backlog, Diabetes Drug Side Effects, Petroselinum Sativum, and MORE! appeared first on The Robert Scott Bell Show.

The post Parthenium Hysterophorus appeared first on The Robert Scott Bell Show.

Monday on The Robert Scott Bell Show:

Hour 1

Democrat State Officials Want Faith Leaders To Convince Religious Groups To Get Vaccinated In an October 30, 2026, investigation published by The Daily Wire, reporter Megan Brock examines Pennsylvania government efforts to enlist religious leaders in campaigns encouraging vaccination, particularly among Amish communities where immunization rates have historically been lower than those of the general population. Documents obtained through public records requests show that Pennsylvania’s Vaccine Education Workgroup, established under an October 2025 executive order by Democratic Governor Josh Shapiro, identified pastors, congregational leaders and faith-based organizations as influential messengers capable of increasing public acceptance of vaccines. The workgroup, led by state Health Secretary Dr. Debra Bogen, discussed maintaining relationships developed during the COVID-19 pandemic between public health agencies, religious institutions and community organizations. Meeting records from December 2025 and April 2026 describe efforts to strengthen vaccine safety messaging, counter information considered misleading by state officials and encourage clinicians to communicate more confidently with vaccine-hesitant families. The group also considered promoting vaccination as a social expectation through healthcare providers, churches, community representatives and advertising. The initiative comes amid measles outbreaks affecting Pennsylvania communities, including Lancaster County, home to a large Amish population. The Pennsylvania Department of Health told The Daily Wire that it had organized more than 230 community vaccination clinics and administered over 6,700 measles, mumps and rubella vaccine doses through those events since late April. Department spokesperson Neil Ruhland maintained that the state’s approach emphasizes accurate information and voluntary medical decisions rather than pressuring individuals to violate their beliefs. Religious liberty advocates expressed a different perspective. Michael Geer, president of the Pennsylvania Family Council, and Kurt Weaver, director of the Church Ambassador Network, argued that government agencies should not treat pastors as instruments for influencing private medical decisions. The article also examines growing disputes over religious and philosophical exemptions from school vaccination requirements. Pennsylvania Democratic Senator Amanda Cappelletti announced plans in September 2026 to introduce legislation eliminating religious vaccination exemptions, while Amish schools in New York have sought Supreme Court review of litigation challenging that state’s restrictions. Brock further discusses Shapiro’s decision to direct Pennsylvania agencies toward vaccination guidance from medical organizations such as the American Academy of Pediatrics rather than relying exclusively on recommendations from the federal Advisory Committee on Immunization Practices. A separate Pennsylvania proposal would have expanded vaccination reporting requirements and permitted exclusion of students considered susceptible to certain infectious diseases, but the proposal was withdrawn following public opposition, with officials indicating that revisions could be introduced later. The report also highlights Pennsylvania’s vaccine manufacturing industry and Shapiro’s public statements about its economic importance. The central controversy is whether partnerships between public health officials and religious leaders represent appropriate community outreach or risk compromising religious independence and informed medical choice. The records document government efforts to encourage vaccination through trusted community figures, but they do not establish that clergy were compelled to participate or that individuals were vaccinated without consent.

FDA plans to update infant formula nutrition requirements for first time in nearly 30 years In an October 29, 2026, CNN report, health journalist Brenda Goodman examines the Food and Drug Administration’s proposal to modernize nutritional requirements for infant formula for the first time since 1998. The proposed changes are part of Operation Stork Speed, an initiative announced by the Trump administration in March 2025 to improve infant formula safety, nutritional quality and availability. The FDA’s initial review addresses eight of the 30 nutrients currently regulated in infant formula, proposing changes to iodine, manganese, vitamin A and vitamin D while reaffirming existing requirements for chloride, potassium, selenium and sodium. Iodine, which supports thyroid hormone production and neurological development, would have its minimum required concentration increased from 5 to 15 micrograms per 100 calories, with a new maximum of 50 micrograms. Manganese, a mineral necessary for normal enzyme function and bone development, would have its minimum reduced from 5 to 1 microgram per 100 calories, with an upper limit of 50 micrograms. The proposal would also double the minimum vitamin D requirement from 1 to 2 micrograms per 100 calories and raise the maximum to 3 micrograms. Vitamin D is essential for calcium absorption and bone development, particularly during infancy when nutritional deficiencies can affect skeletal growth. For vitamin A, the agency proposes revising both minimum and maximum levels, updating the measurement system and counting only preformed vitamin A toward the required amounts rather than including beta-carotene. The review reflects scientific developments in understanding infant nutritional requirements and the composition of human breast milk, which formula manufacturers seek to approximate. FDA Acting Commissioner Kyle Diamantas described the initiative as an effort to align longstanding federal standards with contemporary nutritional research. The agency also requested public input on whether additional ingredients commonly included in commercial formulas, such as docosahexaenoic acid, arachidonic acid and L-carnitine, should become mandatory. These nutrients have been studied for their roles in brain development, growth and other physiological processes, although the evidence supporting particular formulations and concentrations varies. The FDA plans to conduct the broader review in three phases, eventually examining the remaining required nutrients, potential additional ingredients and carbohydrate sources. The agency intends to combine the results into a comprehensive final rule after receiving public comments. Manufacturers would receive a proposed three-year compliance period following the final rule’s effective date to adjust formulations and labeling. Separately, the FDA released new contaminant testing information, reporting that most sampled infant formulas contained low or nondetectable levels of the chemicals examined. The proposed nutritional revisions are not described as a response to an immediate safety emergency. Rather, they represent an effort to update decades-old standards while considering manufacturing feasibility, product availability and the nutritional needs of infants who depend on formula as their primary food source.

Eating disorders are on the rise. GLP-1s could make things worse. In an October 30, 2026, article published by MIT Technology Review, biotechnology journalist Jessica Hamzelou examines growing concerns that the expanding use of GLP-1 weight-loss medications could aggravate eating disorders or contribute to their development in vulnerable individuals. The report draws on a new global analysis estimating that the incidence of anorexia nervosa and bulimia nervosa increased by approximately 71% between 1990 and 2023, with an estimated 18.1 million people worldwide living with one of those two conditions by 2023. Because the analysis did not include every eating disorder, researchers and clinicians believe the overall burden is considerably greater. Clinical psychologist Cheri Levinson of the University of Louisville, who has specialized in eating disorders for nearly two decades, reports seeing increasingly severe cases, including among younger children. She and other specialists identify social media, appearance-related pressures, restrictive dieting and individual susceptibility as potential contributors, although the global study did not determine the causes of the observed increase. The article focuses particularly on medications that mimic glucagon-like peptide-1, a hormone involved in appetite regulation, blood sugar control and feelings of fullness. Drugs in this category have demonstrated important benefits for patients with obesity and type 2 diabetes, but their appetite-suppressing effects may present additional risks for people with restrictive eating disorders. A small study conducted by Levinson and colleagues found that approximately 30% of participants with eating disorders had used GLP-1 medications, while about 10% appeared to have misused them. Those findings concern a specific study population and should not be interpreted as representative of everyone prescribed these medications. Levinson reports encountering patients who developed eating disorders after receiving GLP-1 prescriptions for other medical reasons, as well as young people obtaining weight-loss products through social media and unregulated sources. Cynthia Bulik, a clinical psychologist at the University of North Carolina, warns that these medications could accelerate weight loss in people with anorexia nervosa, potentially allowing severe malnutrition to develop before treatment begins. At the same time, researchers acknowledge that GLP-1 medications might benefit selected patients with certain eating disorders, particularly where uncontrolled binge eating or metabolic disease is involved. The effects are therefore not uniform across diagnoses or individuals. The article also cites growing access to weight-loss medications, including newer formulations and products obtained from compounding pharmacies or questionable online sellers, as reasons for increased clinical vigilance. Recent research and clinical recommendations call for screening patients for eating disorders before prescribing GLP-1 medications, providing education about potential risks and monitoring patients for changes in eating behavior, nutritional status and psychological well-being. The broader issue is how clinicians can preserve the established medical benefits of these drugs while identifying people for whom appetite suppression and rapid weight loss could worsen an existing psychiatric condition. The article does not establish that GLP-1 medications caused the decades-long rise in eating disorders, but it identifies an emerging concern requiring further research and individualized prescribing decisions.

FDA’s New Guidance Could Mean Fewer Supplement Choices In an October 29, 2026, article, the Alliance for Natural Health USA warns that newly finalized Food and Drug Administration guidance concerning new dietary ingredients could increase regulatory costs, discourage product development and ultimately reduce the range of nutritional supplements available to American consumers. The dispute centers on the regulatory framework established by the Dietary Supplement Health and Education Act of 1994, which distinguishes dietary ingredients marketed before October 15, 1994, from newer ingredients that may be subject to additional notification requirements. Manufacturers introducing certain new dietary ingredients must notify the FDA at least 75 days before marketing and provide information supporting a reasonable expectation of safety under the proposed conditions of use. The guidance describes the kinds of documentation, scientific evidence and testing that the agency considers appropriate when evaluating those submissions. ANH argues that these expectations could create substantial obstacles for smaller supplement companies, particularly those developing products from herbs with long histories of traditional use but limited modern toxicological documentation. The organization contends that requiring detailed historical records or additional safety studies may be financially unrealistic for companies with modest research budgets. Another concern involves higher-dose supplements. When companies rely on animal studies to establish safety, the FDA recommends applying uncertainty factors when estimating acceptable human exposure levels. ANH argues that these calculations could make it difficult for manufacturers to justify higher serving sizes without conducting additional research, potentially leading them to reduce dosages or abandon certain products. The organization also questions how the guidance may affect improved formulations designed to increase nutrient absorption or alter the delivery of an established ingredient. Even when the underlying substance has previously been studied, changes in manufacturing or bioavailability may require additional evidence demonstrating that the new version remains safe. ANH maintains that such requirements could discourage innovation and disproportionately benefit larger manufacturers capable of absorbing regulatory expenses. It also raises concerns that the resulting costs could be passed along to consumers through higher prices. The FDA’s regulatory rationale is that historical consumption alone does not necessarily establish safety at every dose, in every formulation or for every population. Changes in concentration, chemical composition and absorption can alter a substance’s biological effects, making appropriate safety documentation relevant to consumer protection. The guidance itself does not automatically ban the supplements discussed in the article, and ANH’s predictions about reduced product availability are prospective concerns rather than documented market outcomes. The organization urges the FDA to give greater weight to credible historical use and existing scientific research while connecting additional testing requirements to identifiable safety questions. Its broader argument is that consumer protection should include both reasonable evidence of product safety and a regulatory pathway that remains accessible to smaller companies developing nutritional products. The controversy illustrates the continuing tension between supplement industry innovation, consumer choice, regulatory oversight and the level of scientific evidence needed before new ingredients reach the market.

Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!

Today’s Homeopathic Hit is Parthenium hysterophorus, or Bitter-broom (Escoba Amargo).

Boericke describes a Cuban remedy historically associated with malarial fever, head and sensory complaints, left-sided abdominal pain, menstrual disturbance, and debility.

Download the  Information Sheet

Hour 2

DISCUSSION: What is Real Food and can it extend lifespan and health-span? With growing attention on the connection between nutrition, chronic disease, and longevity, the question deserves more than a slogan or a catchy government campaign. Can replacing ultra-processed foods with whole, nutrient-dense alternatives really add five years or more to your life? What does the scientific evidence actually show, and is there a difference between simply living longer and living healthier? What qualifies as real food, what does the research reveal about its potential to prevent disease and support longevity, and why is something as fundamental as what we put on our plates one of the most powerful tools we have for reclaiming our health.

CRISPR Gene-Edited Strawberries Have Entered the U.S. Food Supply Without Required Labeling In an October 31, 2026, report published on Focal Points, epidemiologist Nicolas Hulscher raises concerns about the introduction of CRISPR gene-edited strawberries into the American food supply without mandatory disclosure to consumers purchasing meals from restaurants and other foodservice establishments. According to information cited from the Canadian Biotechnology Action Network, agricultural company J.R. Simplot confirmed in early 2026 that limited quantities of its genetically engineered strawberries were being distributed through its U.S. wholesale foodservice business. Simplot developed the strawberries in partnership with Plant Sciences Inc., using CRISPR-Cas9 gene-editing technology to modify a gene involved in flowering regulation. A scientific presentation from the company identifies the targeted gene as Gn1 and explains that researchers disabled its function to alter flowering patterns and extend the plants’ fruit-producing season. The intended agricultural benefit is a longer period of strawberry production, potentially improving supply consistency and increasing the availability of fresh fruit. The article reports that Simplot has not publicly identified the restaurants or other foodservice businesses purchasing the strawberries, making it difficult for consumers to determine where the product is being served. Hulscher also reviews the regulatory history of the genetically edited fruit. The U.S. Department of Agriculture determined in August 2020 that the strawberries were not subject to its biotechnology regulations, while the Food and Drug Administration documented a voluntary premarket consultation concerning the modification on December 4, 2024. These regulatory interactions are important because gene editing does not necessarily involve introducing DNA from an unrelated species, and different genetic modifications can be subject to different federal oversight requirements. Hulscher’s principal concern involves consumer disclosure. Under the USDA’s National Bioengineered Food Disclosure Standard, restaurants and similar retail foodservice establishments are exempt from mandatory bioengineered-food labeling requirements. Consequently, consumers may encounter foods produced through genetic engineering without receiving information about the technology used in their development. The article does not report evidence that these strawberries have caused adverse health effects, nor does it present findings demonstrating that the particular genetic modification makes them unsafe. Its emphasis is instead on transparency, consumer choice and whether existing federal disclosure rules adequately address emerging agricultural biotechnology. The broader issue is how regulators should evaluate and communicate the use of increasingly precise gene-editing methods as genetically modified crops move from experimental development into commercial distribution.

Why Are Food Dyes Still in Halloween Candy? In an October 31, 2026, article published by The MAHA Report, Catherine Ebeling examines why many popular Halloween candies continue to contain petroleum-derived synthetic food dyes despite federal efforts to encourage manufacturers to eliminate them. The issue follows an April 22, 2025, announcement by the Department of Health and Human Services and the Food and Drug Administration outlining plans to phase out six widely used synthetic color additives, including Red No. 40, Yellow No. 5, Yellow No. 6, Blue No. 1, Blue No. 2 and Green No. 3. However, the initiative largely relies on voluntary commitments from manufacturers, with company deadlines extending through the end of 2027. Unlike a binding prohibition, these voluntary targets do not automatically trigger enforcement actions when companies fail to meet them. A separate FDA decision banning Red No. 3 establishes a mandatory compliance deadline of January 15, 2027, for food products. Ebeling reports that progress has been uneven across the food industry. Some major manufacturers, including Nestlé USA, Tyson Foods and Campbell’s, have removed synthetic dyes from their American product lines, while General Mills has eliminated them from foods supplied to schools. Candy manufacturers have generally moved more slowly. Hershey committed in July 2025 to eliminating synthetic dyes from its U.S. products by the end of 2027, but products such as Jolly Rancher, Twizzlers and Reese’s Pieces continued using synthetic colors during the 2026 Halloween season. Mars initially resisted making a timetable commitment but subsequently introduced naturally colored versions of selected products, including M&M’s, Skittles and Starburst, primarily through online sales. Other companies, including Ferrero and Mondelēz, have taken different approaches to reformulation and compliance. Ebeling discusses research examining possible health effects of synthetic dyes, including hypersensitivity reactions and changes in children’s behavior. She cites a 2007 University of Southampton study and a 2021 California environmental health assessment that identified evidence associating certain synthetic dyes with adverse neurobehavioral outcomes in some children. These findings do not establish that every synthetic dye causes the same effects or that exposure produces identical outcomes in all children. The article also highlights state-level restrictions adopted in California, West Virginia and Texas, along with legal challenges involving the food and dye industries. Ebeling identifies alternatives available to consumers, including products without added synthetic coloring and candies formulated with ingredients such as beet juice, turmeric and spirulina. Her central argument is that voluntary federal commitments have produced uneven changes, leaving families to examine ingredient labels while manufacturers complete reformulation. The broader debate concerns the adequacy of existing food additive regulations, the strength of scientific evidence regarding particular dyes and whether consumer protection should rely on voluntary industry changes or enforceable restrictions.

We Beat The Big Bad Wolf! In an October 29, 2026, announcement, the Informed Consent Action Network reports that a proposed class action lawsuit against pharmaceutical manufacturer GlaxoSmithKline has reached a settlement involving allegations of misleading advertising for the company’s Tdap vaccine. The litigation concerns GSK’s “Big Bad Cough” advertising campaign, introduced in 2015, which encouraged adults, particularly grandparents, to receive a pertussis-containing vaccine to help protect infants from whooping cough. The advertisements used imagery inspired by the Big Bad Wolf to emphasize the potential danger of adults transmitting pertussis to vulnerable babies. According to ICAN, the plaintiffs alleged that the campaign created a misleading impression that receiving Tdap would prevent vaccinated adults from becoming infected with or transmitting the bacteria responsible for pertussis. The lawsuit was filed in August 2021 by attorneys from Siri & Glimstad, with financial and organizational support from ICAN. The organization states that GSK discontinued the advertising campaign shortly after the litigation began and that a settlement has now been reached for eligible New York residents who received vaccination in response to the challenged advertisements. The dispute centers on an important distinction between protection against disease and prevention of infection or transmission. Pertussis vaccines are intended to reduce the risk of whooping cough, but vaccination does not guarantee that a person cannot become infected or transmit the bacterium. Research has also examined the possibility of vaccinated individuals carrying pertussis bacteria without developing characteristic symptoms. These findings have implications for how vaccine manufacturers describe the protective benefits of their products, particularly when advertisements imply that vaccination eliminates the possibility of transmitting an infection to another person. ICAN argues that the advertising campaign overstated the vaccine’s effects and used emotional messaging about protecting grandchildren to influence consumers’ medical decisions. The organization characterizes the settlement as a significant development in litigation involving vaccine advertising, noting that legal actions against vaccine manufacturers can face substantial procedural and statutory obstacles. However, the announcement does not provide the settlement’s financial terms, the number of eligible class members or a judicial finding establishing that GSK committed false advertising. A negotiated settlement does not necessarily constitute an admission of wrongdoing by the defendant. The announcement also does not establish that Tdap vaccination lacks benefits in preventing serious pertussis disease. The broader significance of the case concerns the accuracy of pharmaceutical advertising, the distinction between different forms of vaccine protection and the information consumers should receive when making vaccination decisions.

McDonald’s dealt legal setback as judge allows McRib meat lawsuit to proceed In an October 31, 2026, report by Brittany Miller for FOX Local, a federal judge in Chicago ruled that McDonald’s must continue defending portions of a proposed class action lawsuit alleging that its McRib sandwich misleads consumers about the type of pork used in the product. U.S. District Judge April Perry rejected the company’s request to dismiss the entire case, allowing claims involving consumer deception, fraud and unjust enrichment to proceed while dismissing five other claims without prejudice. The lawsuit, filed by four consumers in December, argues that the sandwich’s name, distinctive rib-shaped patty and promotional materials create the impression that the product contains actual pork rib meat. According to the plaintiffs, consumers may reasonably expect a sandwich marketed as the McRib to contain a more expensive cut of pork rather than meat obtained from other parts of the animal. The complaint alleges that the product instead contains lower-cost pork ingredients, including shoulder meat and certain organ or stomach tissues. McDonald’s disputes those allegations and maintains that the McRib contains 100% pork sourced from American farmers and suppliers. The company has specifically denied using heart, tripe or scalded stomach in the patty. McDonald’s also argues that its publicly available ingredient information identifies pork as the primary ingredient and that the sandwich’s trademarked name should not be interpreted as a literal representation of its anatomical composition. Judge Perry concluded that the plaintiffs had presented sufficient allegations for certain claims to proceed, including consumer survey evidence addressing expectations about the product. One survey cited in the court filing found that 72% of respondents expected the McRib to contain rib meat, while another indicated that 67% considered the presence of rib meat important or very important to their purchasing decision. The judge determined that these findings warranted further examination rather than dismissal at the preliminary stage. She also rejected the argument that the trademarked name alone protected McDonald’s from potential deceptive marketing claims, noting that other menu items, including the McChicken and Egg McMuffin, have names that communicate information about their ingredients. The McRib was introduced in 1981 and has become a recognizable limited-time offering featuring a boneless pork patty shaped to resemble ribs, barbecue sauce, onions and pickles. The ruling does not establish that McDonald’s violated consumer protection laws or that the plaintiffs’ allegations about the meat’s composition are accurate. It allows the remaining claims to proceed through additional litigation, where evidence concerning ingredients, advertising practices and consumer expectations may be examined. The broader issue is how food manufacturers may use product names, visual presentation and marketing to describe ingredients, and when those representations could become misleading under consumer protection laws.

Remember Friends, The Power to Heal is Yours!

The post Faith Leaders Vaccine Push, FDA Infant Formula Reform, GLP-1 Eating Disorder Risks, Supplement Freedom Threats, Parthenium Hysterophorus, Real Food Definition, Healthy Eating Denial, Unlabeled Gene Edited Strawberries, Halloween Candy Dyes, Vaccine Advertising Settlement, McRib Lawsuit, and MORE! appeared first on The Robert Scott Bell Show.